

# Research Toward a Cure September 16, 2024

**Table 1. Current Clinical Trials**

Trial	Trial Registry Identifier(s)	Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>ADOPTIVE IMMUNOTHERAPY</b>				
<b>AutoRESIST:</b> HIV antigen-specific T-cells targeting conserved epitopes for treatment of HIV-associated lymphoma	<a href="#">NCT04975698</a>	Catherine Bollard, Children's Research Institute	Phase II	June 2026
<b>AlloRESIST:</b> Evaluate the safety, immunologic, and virologic responses of donor derived HIV-specific T-cells in HIV+ individuals following allogeneic bone marrow transplantation	<a href="#">NCT04248192</a>	Catherine Bollard, Children's Research Institute	Phase I	April 2025
<b>HST-NEETs:</b> HIV-1 specific T-cells for HIV+ individuals	<a href="#">NCT03485963</a> (closed to enrollment)	Children's Research Institute	Phase I	December 2024 2024 ASGCT Meeting, <a href="#">Abstract 1908</a> 2022 ASH Meeting, <a href="#">Abstract 3339</a>
<b>ANALYTICAL TREATMENT INTERRUPTION</b>				
Assessment of HIV remission in early treated individuals with the MHC B35/53Bw4TTC2 genotype	<a href="#">NCT05482854</a>	ANRS	N/A	July 2025
<b>SCOPE-ATI</b>	<a href="#">NCT04359186</a>	UCSF	N/A	June 2026 CROI 2024, Abstracts <a href="#">446</a> , <a href="#">482</a> <a href="#">Strategies for an HIV Cure 2023</a> , <a href="#">Abstract PP64</a>
Imaging and biopsy of people with HIV undergoing ATI	<a href="#">NCT05419024</a>	National Cancer Institute (NCI)	Phase II	August 2026 CROI 2024, <a href="#">Abstract 502</a> <a href="#">Strategies for an HIV Cure 2023</a> , <a href="#">Abstract PP41</a> <a href="#">Front Med. 2022 Aug 22;9:979756.</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 1. Current Clinical Trials (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>ANTI-<math>\alpha</math>4<math>\beta</math>7 INTEGRIN ANTIBODIES</b>				
<b>vedolizumab</b> (anti- $\alpha$ 4 $\beta$ 7 integrin antibody)	<a href="#">NCT03147859</a>	Ottawa Hospital Research Institute	Phase II	December 2023 <a href="#">BMJ Open. 2020; 10(10):e041359.</a> CROI 2019, <a href="#">Abstract 393</a>
<b>ANTI-INFLAMMATORY</b>				
Fecal Microbiota Transplantation (FMT)	<a href="#">NCT06022406</a>	Jean-Pierre Routy, McGill University Health Centre	Phase II	September 2025
<b>BCL-2 ANTAGONISTS</b>				
<b>venetoclax</b>	<a href="#">NCT05668026</a>	University of Aarhus	Phase I/IIb	March 2026
<b>BISPECIFIC T-CELL ENGAGERS</b>				
<b>GS-8588</b>	No clinicaltrials.gov entry, <a href="#">listed on UPenn website</a>	Gilead Sciences	Phase I	N/A
<b>BROADLY NEUTRALIZING ANTIBODIES</b>				
<b>VRC01</b> (analytical treatment interruption in HVTN 703/HPTN 081 AMP trial participants)	<a href="#">NCT04860323</a> (closed to enrollment)	HIV Vaccine Trials Network	N/A	February 2025
<b>10-1074-LS + 3BNC117-LS</b> in primary HIV infection	<a href="#">NCT04319367</a>	Imperial College London	Phase II	July 2027 <a href="#">IAS HIV Cure &amp; Immunotherapy Forum 2023</a> HIV Persistence Workshop 2022, <a href="#">Abstracts OP 7.2, PP 8.11 (slides)</a> <a href="#">Trials. 2022 Apr 5;23(1):263</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>BROADLY NEUTRALIZING ANTIBODIES (Cont.)</b>				
3BNC117-LS + 10-1074-LS	<a href="#">NCT06205602</a> (not yet open for enrollment)	AIDS Clinical Trials Group	Phase II	February 2029
3BNC117-LS + 10-1074-LS	<a href="#">NCT05300035</a>	French National Agency for Research on AIDS and Viral Hepatitis (ANRS)	Phase II	December 2028
VRC07-523LS + PGT121.414.LS	<a href="#">NCT05719441</a>	NIAID	Phase II	September 2028
Tatelo Plus: PGDM1400LS, VRC07-523LS, PGT121.414.LS	<a href="#">NCT06508749</a> (not yet open for enrollment)	NIAID	Phase I/II	February 2028
3BNC117-LS-J + 10-1074-LS-J	<a href="#">NCT06031272</a>	ACTG	Phase I	June 2026
3BNC117-LS + 10-1074-LS	<a href="#">NCT05612178</a>	NIAID	Phase I	December 2025
AAV8-VRC07 (broadly neutralizing antibody delivered by AAV vector)	<a href="#">NCT03374202</a> (closed to enrollment)	NIAID	Phase I	August 2026 <a href="#">Nat Med.</a> <a href="#">28(5):1022-1030.</a> CROI 2022, <a href="#">Abstract 498</a> CROI 2021, <a href="#">Abstract 160,</a> <a href="#">Webcast</a> CROI 2020, <a href="#">Abstract 41LB,</a> <a href="#">Webcast</a>
CAP256V2LS + VRC07-523LS	<a href="#">PACTR202309578224660</a> (not yet open for enrollment)	Centre for the AIDS Programme of Research in South Africa (CAPRISA)	Phase I	October 2025
<b>CD4 ATTACHMENT INHIBITORS</b>				
UB-421 (antibody inhibitor of HIV binding to CD4 receptors)	<a href="#">NCT04404049</a> (not yet open for enrollment)	UBP Greater China (Shanghai) Co., Ltd	Phase II	June 2025
<b>COMBINATIONS</b>				
VRC07-523LS, CAP256V2LS, vesatolimod	<a href="#">NCT05281510</a> (closed to enrollment)	Gilead Sciences	Phase IIa	March 2025

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>COMBINATIONS (Cont.)</b>				
<b>budigalimab</b> (anti-PD-1 antibody) +/- <b>ABBV-382</b> (anti- $\alpha_4\beta_7$ integrin antibody)	<a href="#">NCT06032546</a>	AbbVie	Phase II	October 2026
<b>UB-421 + chidamide</b> (antibody inhibitor of HIV binding to CD4 receptors + HDAC inhibitor)	<a href="#">NCT04985890</a> (not yet open for enrollment)	UBP Greater China (Shanghai) Co., Ltd	Phase II	December 2027
<b>Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS</b> (therapeutic vaccines, broadly neutralizing antibodies)	<a href="#">NCT04983030</a>	Boris Juelg, MD PhD	Phase I/IIa	April 2026
<b>ChAdOx1.tHIVconsV1, ChAdOx1.HIVconsV62, MVA.tHIVconsV3, MVA.tHIVconsV4, 3BNC117-LS, 10-1074-LS, vesatolimod</b>	<a href="#">NCT06071767</a>	NIAID	Phase I/IIa	April 2026
<b>IMPAACT P1115 v2.0:</b> Very early intensive treatment of infants with HIV to achieve remission (ART +/- VRC01)	<a href="#">NCT02140255</a>	IMPAACT	Phase I/II	December 2031 CROI 2024, Abstracts <a href="#">184</a> , <a href="#">954</a> <a href="#">Lancet HIV. S2352-3018(23)00236-9.</a> <a href="#">Strategies for an HIV Cure 2023,</a> <a href="#">Abstract PP05</a> CROI 2022, <a href="#">Abstract 31</a>
Therapeutic conserved element DNA vaccine ( <b>IL-12 adjuvanted p24CE</b> ), MVA vaccine boost ( <b>MVA/HIV62B</b> ), TLR9 agonist ( <b>lefitolimod</b> ), broadly neutralizing antibodies ( <b>VRC07-523LS + 10-1074</b> )	<a href="#">NCT04357821</a> (closed to enrollment)	UCSF	Phase I/II	December 2025 CROI 2024, Abstracts <a href="#">446</a> , <a href="#">618</a> <a href="#">HIV Res Clin Pract. 25(1):2312318</a> <a href="#">Strategies for an HIV Cure 2023,</a> <a href="#">Abstract PP66</a> CROI 2023, <a href="#">Abstract 435</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 1. Current Clinical Trials (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>COMBINATIONS (Cont.)</b>				
<b>HVRRICANE:</b> HIVIS DNA + MVA-CMDR vaccines +/- TLR4 agonist	<a href="#">NCT04301154</a> (closed to enrollment)	PENTA Foundation	Phase I	February 2025 CROI 2024, <a href="#">Abstract 408</a>
<b>N-803</b> (recombinant human super agonist interleukin-15 complex) +/- <b>VRC07-523LS + 10-1074</b>	<a href="#">NCT04340596</a>	NIAID	Phase I	April 2026
<b>N-803, 3BNC117-LS, 10-1074-LS</b>	<a href="#">NCT05245292</a>	Rockefeller University	Phase I	December 2025
<b>VRC07-523LS, PGDM1400LS, ChAdOx1.tHIVconsV1, ChAdOx1.HIVconsV62, MVA.tHIVconsV4, A244d11 gp120/ALFQ</b>	<a href="#">NCT06484335</a> (not yet open for enrollment)	Henry M. Jackson Foundation for the Advancement of Military Medicine	Phase I	August 2027
<b>CYTOKINES</b>				
<b>N-803</b> in acute HIV infection	<a href="#">NCT04505501</a>	Thai Red Cross AIDS Research Centre	Phase II	June 2025
<b>GENE THERAPIES</b>				
<b>EBT-101</b> (CRISPR/Cas9 targeting HIV provirus)	<a href="#">NCT05144386</a> (closed to enrollment)	Excision BioTherapeutics	Phase I/IIa	May 2025 ESGCT Congress 2023, <a href="#">Abstract OR31</a>
<b>LVgp120duoCAR-T cells</b>	<a href="#">NCT04648046</a>	Steven Deeks, UCSF	Phase I/IIa	December 2028
<b>Cal-1:</b> Dual anti-HIV gene transfer construct	<a href="#">NCT02390297</a> (closed to enrollment)	Calimmune	Phase I/II	October 2031 CROI 2020, <a href="#">Abstract 338</a>
An ATI study to evaluate the impact of <b>AGT103-T</b> to suppress HIV replication in the absence of ART	<a href="#">NCT05540964</a> (enrolling by invitation)	American Gene Technologies International Inc.	Phase I	July 2025 <a href="#">Front Med. 11:1342476.</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 1. Current Clinical Trials (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>GENE THERAPIES (Cont.)</b>				
CD4 CAR + SB-728mR modified T cells	<a href="#">NCT03617198</a> (closed to enrollment)	University of Pennsylvania	Phase I	December 2027 <a href="#">CROI 2022</a> <a href="#">(James L. Riley)</a>
Chimeric Antigen Receptor (CAR)-T cell therapy	<a href="#">NCT03240328</a>	Guangzhou 8th People's Hospital	Phase I	December 2030 <a href="#">JCI. 2021;150211</a>
<b>CMV-specific HIV-CAR T Cells</b>	<a href="#">NCT06252402</a>	City of Hope Medical Center	Phase I	December 2026
<b>EBT-101</b> (long-term follow-up study)	<a href="#">NCT05143307</a> (enrolling by invitation)	Excision BioTherapeutics	Phase I	April 2037
Long-term follow-up of study participants treated with <b>AGT103-T</b>	<a href="#">NCT05529342</a> (enrolling by invitation)	American Gene Technologies International Inc.	Phase I	September 2038
<b>SB-728mR-HSPC</b> (autologous hematopoietic stem/progenitor cells modified at the CCR5 gene)	<a href="#">NCT02500849</a> (closed to enrollment)	City of Hope Medical Center	Phase I	August 2024
<b>GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS</b>				
Stem cells gene-modified with CCR5 shRNA/TRIM5alpha/TAR decoy	<a href="#">NCT02797470</a> (closed to enrollment)	AIDS Malignancy Consortium	Phase I/II	June 2025
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)	<a href="#">NCT02337985</a> (closed to enrollment)	City of Hope Medical Center	Phase I	December 2024
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ) + busulfan	<a href="#">NCT01961063</a> (closed to enrollment)	City of Hope Medical Center	Phase I	December 2024
<b>IMAGING STUDIES</b>				
Imaging immune activation in HIV by PET-MR	<a href="#">NCT03684655</a>	University of California, San Francisco	Phase I	November 2024 <a href="#">CROI 2024</a> , <a href="#">Abstract 105</a>
Radiolabeled VRC01	<a href="#">NCT03729752</a>	University of California, San Francisco	Phase I	January 2025 <a href="#">Nat Commun. 2022;13(1):1219.</a> <a href="#">CROI 2020</a> , <a href="#">Abstract 72</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 1. Current Clinical Trials (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>IMMUNE CHECKPOINT INHIBITORS</b>				
<b>ASC22</b> (anti-PD-L1 antibody)	<a href="#">NCT05330143</a>	Asclepis Pharmaceuticals Co., Ltd.	Phase II	December 2023
<b>NIVO-LD</b> : Low dose <b>nivolumab</b> in adults living with HIV on antiretroviral therapy	<a href="#">NCT05187429</a>	University of Melbourne	Phase I/II	January 2026
<b>nivolumab</b> (anti-PD-1 antibody) + <b>ipilimumab</b> (anti-CTLA-4 antibody) in treating patients with advanced HIV associated solid tumors	<a href="#">NCT02408861</a>	National Cancer Institute (NCI)	Phase I	August 2024 AIDS 2024, <a href="#">Abstract OAA1308 Cancer. 2023 Nov 14.</a> <a href="#">Clin Infect Dis. 2021 ciaa1530</a> HIV Persistence Workshop 2019, <a href="#">Abstract OP 5.5 J. Clin Oncol 36, no. 15 suppl</a>
<b>IMMUNOMODULATORS</b>				
<b>lenalidomide, adenosylmethionine</b>	<a href="#">NCT05598580</a>	First Affiliated Hospital of Zhejiang University	Phase IV	November 2024
<b>JANUS KINASE INHIBITORS</b>				
<b>baricitinib</b>	<a href="#">NCT05452564</a>	Emory University	Phase II	January 2028
<b>LATENCY-REVERSING AGENTS</b>				
<b>lauric acid</b>	<a href="#">NCT05687565</a>	Hospital Universitari Vall d'Hebron Research Institute	N/A	December 2025
<b>panobinostat, lenalidomide + pyrimethamine</b>	<a href="#">NCT06240520</a> (not yet open for enrollment)	Erasmus Medical Center	Phase I/II	October 2025
<b>topiramate</b>	<a href="#">NCT06282783</a> (not yet open for enrollment)	Erasmus Medical Center	Phase I/II	August 2025
<b>arsenic trioxide</b>	<a href="#">NCT03980665</a>	Guangzhou 8th People's Hospital	Phase I	December 2025
<b>decitabine, romidepsin</b>	<a href="#">NCT05230368</a>	ANRS	Phase I	April 2026

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>STEM CELL TRANSPLANTATION</b>				
Analytical treatment interruption in PWHIV post-allogeneic stem cell transplantation from a CCR5 delta32 homozygous donor	<a href="#">NCT06582797</a> (not yet open for enrollment)	University of Kansas Medical Center	N/A	September 2024
<b>T-CELL RECEPTOR-BASED BISPECIFICS</b>				
IMC-M113V in HLA-A*02:01 positive people	<a href="#">2021-002008-11</a>	Immunocore	Phase I/II	N/A
<b>THERAPEUTIC VACCINES</b>				
<b>BELIEVE:</b> BCG vaccination effect on latent reservoir size in treated HIV-1 infection	<a href="#">NCT05004038</a> (closed to enrollment)	University of Zurich	Phase IIa	January 2024
<b>HB-502/HB-501</b> (arenavirus vaccine vectors)	<a href="#">NCT06430905</a>	Hookipa Biotech GmbH	Phase Ib	November 2025
<b>GS-1966/GS-1144</b> HIV vaccine regimens	No clinicaltrials.gov entry, <a href="#">#7 on Midway Research Center list</a>	Gilead Sciences	Phase Ib	N/A
HIV Env mosaic immunogens <b>MOS1SIP, MOS2SIP, M3SIP8 + MPLA-5</b> adjuvant ( <i>*primarily focused on preventive HIV vaccine development but may also assist cure research</i> )	<a href="#">NCT06449196</a> (not yet open for enrollment)	IAVI	Phase I	December 2025
<b>426c.Mod.Core-C4b, 3M-052-AF + Alum</b> ( <i>*primarily focused on preventive HIV vaccine development but may also assist cure research</i> )	<a href="#">NCT06006546</a>	NIAID, HIV Vaccine Trials Network	Phase I	December 2025
<b>ChAdOx1.HIVconsV62-MVA.tHIVconsV4 (C62-M4), ChAdOx1.tHIVconsV1+C62-MVA.tHIVconsV3+M4 (C1C62-M3m4)</b>	<a href="#">NCT05604209</a>	University of North Carolina, Chapel Hill	Phase I	October 2024
<b>DC-HIV04:</b> a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides	<a href="#">NCT03758625</a> (closed to enrollment)	Sharon Riddler, University of Pittsburgh	Phase I	March 2025

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)



# Research Toward a Cure September 16, 2024

**Table 1. Current Clinical Trials (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>THERAPEUTIC VACCINES (Cont.)</b>				
<b>ICVAX:</b> PD-1-enhanced HIV DNA vaccine	<a href="#">NCT06253533</a> (closed to enrollment)	Shenzhen Immuno Cure Biomedical Company Limited	Phase I	January 2025 AIDS 2024, <a href="#">Abstract TUPEA024 IAS HIV Cure &amp; Immunotherapy Forum 2023</a>
<b>NETI:</b> Trimer 4571 therapeutic vaccination	<a href="#">NCT04985760</a>	NIAID	Phase I	November 2025
Therapeutic vaccine based on aDC1 dendritic cells	<a href="#">NCT05786937</a> (not yet open for enrollment)	University of Sao Paulo General Hospital	Phase I	December 2023
<b>TREATMENT INTENSIFICATION/EARLY TREATMENT</b>				
<b>DGVTAF:</b> Immediate initiation of antiretroviral therapy during "hyperacute" HIV infection	<a href="#">NCT02656511</a> (closed to enrollment)	UCSF	Phase IV	May 2028 <a href="#">J Clin Invest. 2024 Apr 23:e176673. medRxiv 2024.03.27.24304867</a> CROI 2024, Abstracts <a href="#">468</a> , <a href="#">508</a> IAS 2023, <a href="#">Abstract 2167</a> CROI 2023, <a href="#">Abstract 305</a>
<b>AAHIV:</b> Antiretroviral therapy for acute HIV infection	<a href="#">NCT00796263</a>	South East Asia Research Collaboration with Hawaii	Phase III	June 2033 <a href="#">See supplemental references page</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>				
<b>EIT:</b> Early infant HIV treatment in Botswana	<a href="#">NCT02369406</a> (closed to enrollment)	Harvard School of Public Health	Phase II/III	June 2029 <a href="#">JAIDS 2022 Dec 12</a> CROI 2022, <a href="#">Abstract 712 Clin Infect Dis. 2021 ciab143 Clin Infect Dis. 2020 Jan 12. Sci Transl Med. 2019 Nov 27;11(520). pii: eaax7350</a> CROI 2019, <a href="#">Poster abstract 826</a> CROI 2018, <a href="#">Abstract 136</a>
<b>EARLIER:</b> Early ART to limit infection and establishment of reservoir	<a href="#">NCT02859558</a> (closed to enrollment)	AIDS Clinical Trials Group	Phase II	April 2025 <a href="#">AIDS. 2024 Mar 14. Clin Infect Dis. 2021 Aug 2;73(3):e643-e651</a>
<b>TYROSINE KINASE INHIBITORS</b>				
<b>dasatinib</b>	<a href="#">NCT05527418</a>	Eva Bonfill, Institut d'Investigacions Biomèdiques August Pi i Sunyer	Phase II	June 2026
<b>dasatinib</b>	<a href="#">NCT05780073</a>	Fundació Institut Germans Trias i Pujol	Phase II	March 2025

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 2. Current Observational Studies**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
Accurate staging of immuno-virological dynamics during acute HIV infection (ACS)	<a href="#">NCT03449706</a>	University Hospital, Ghent	N/A	January 2028
Analytic treatment interruption (ATI) to assess HIV cure	<a href="#">NCT02437526</a> (enrolling by invitation)	Mayo Clinic	N/A	May 2025 <a href="#">PLoS Med. 2017 Nov 28;14(11):e1002461.</a>
<b>ANRS CO24 OncoVIHAC:</b> Immune checkpoint inhibitors in HIV+ individuals with cancers	<a href="#">NCT03354936</a>	Inserm-ANRS	N/A	June 2022 <a href="#">J Immunother Cancer. 12(8):e009728.</a> <a href="#">Cells. 2022 Mar 17;11(6):1015.</a> AIDS 2020, <a href="#">Abstract OAB0203</a>
<b>APRIL:</b> Analysis of the persistence, reservoir and HIV latency	<a href="#">NCT05752318</a>	University Hospital, Strasbourg, France	N/A	February 2027 <a href="#">Pathog Immun. 8(2):92-114.</a>
<b>ARCH:</b> Analysis of the reservoir in individuals controlling HIV infection	<a href="#">NCT06016114</a> (not yet open for enrollment)	Sponsor University Hospital, Ghent	N/A	October 2028
<b>ATGALIG-HIV:</b> Study of autophagy and the effects of GALIG gene products in HIV-1+ patients on antiretroviral therapy since primary infection, chronic phase, or never treated	<a href="#">NCT04160455</a>	Centre Hospitalier Régional d'Orléans	N/A	November 2039
<b>BICTEVOIR:</b> A study to determine the cartography of virologic reservoir related to antiretroviral concentrations in HIV-1+ patients on first line treatment containing bicitgravir, emtricitabine and tenofovir alafenamide	<a href="#">NCT05222945</a> (not yet open for enrollment)	ANRS	N/A	March 2024
Characterization of acute and recent HIV-1 infections in Zurich: a long-term observational study	<a href="#">NCT00537966</a>	University of Zurich	N/A	January 2025 AIDS 2024, <a href="#">Abstract OAA0204</a> <a href="#">Microorganisms. 12(2):302</a> CROI 2023, <a href="#">Abstract 387</a>

Entries shaded in light grey include analytic treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure September 16, 2024

**Table 2. Current Observational Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>CHRONO</b> : A prospective cohort for ex vivo cure studies with chronic HIV+ patients in the Netherlands	<a href="#">NCT04888754</a> (closed to enrollment)	Erasmus Medical Center	N/A	January 2034
<b>CODEX</b> (the “Extreme” cohort, ANRS CO21)	<a href="#">NCT01520844</a>	Inserm-ANRS	N/A	September 2023 <a href="#">See supplemental references page</a>
Comparing immune activation and HIV reservoir size between PWHIV on tenofovir-containing versus NRTI-free ART	<a href="#">NCT05584397</a> (enrolling by invitation)	University of Washington	N/A	February 2025
Developing a functional cure for HIV disease: Clinical specimen collection from HIV+ individuals	<a href="#">NCT03215004</a> (closed to enrollment)	American Gene Technologies International Inc.	N/A	February 2021
Establish and characterize an acute HIV infection cohort in a high-risk population	<a href="#">NCT00796146</a>	Southeast Asia Research Collaboration with Hawaii	N/A	July 2033 <a href="#">See supplemental references page</a>
Evaluation of the role of HIV-1 Tat protein and anti-Tat immune response in HIV reservoir (ISS OBS T-005)	<a href="#">NCT04263207</a> (suspended)	Barbara Ensoli, MD, PhD, Istituto Superiore di Sanità	N/A	June 2025
Extended follow-up of the ISS T-003 trial volunteers (ISS T-003 EF-UP2020)	<a href="#">NCT05680948</a>	Istituto Superiore di Sanità	N/A	June 2024 AIDS 2024, <a href="#">Abstract OAA1303</a>
<b>EX VIVO</b> : Ex vivo characterization and targeting of the latent HIV infected reservoir to cure HIV	<a href="#">NCT05215704</a>	Erasmus Medical Center	N/A	December 2030
<b>FRESH</b> (Females rising through education, support, and health)	<a href="#">Ragon Institute webpage</a> (no clinicaltrials.gov entry)	Ragon Institute of MGH, MIT and Harvard	N/A	N/A <a href="#">See supplemental references page</a>
<b>HI-ART</b> : Optimising cohorts for HIV cure interventions	<a href="#">NCT05852301</a>	Bayside Health	N/A	December 2025
<b>HIV-Mercuri</b> : HIV study on measuring the reservoir on cellular level to cure infection	<a href="#">NCT04305665</a>	University Hospital, Ghent	N/A	December 2025
HUSH restriction in HIV+ patients	<a href="#">NCT04172480</a>	Inserm-ANRS	N/A	September 2023

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 2. Current Observational Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
<b>iCHIP:</b> Effect of immune checkpoint inhibitors on HIV persistence	<a href="http://hivcure.com.au">hivcure.com.au</a> (no registry entry)	University of Melbourne	N/A	N/A <a href="#">J Immunol Methods. 2021 Dec 1;113198</a> <a href="#">AIDS. 2021 Apr 15.</a> CROI 2020, <a href="#">Abstract 334</a>
<b>IciStem:</b> Collaborative project to guide and investigate the potential for HIV cure in HIV+ patients requiring allogeneic stem cell transplantation for hematological disorders	<a href="#">IciStem website</a> (no clinicaltrials.gov entry)	amfAR	N/A	N/A <a href="#">Nat Med. 2024 Sep 2.</a> <a href="#">Lancet HIV. 11(6):e389-e405.</a> IAS 2023, <a href="#">Abstract OALBA0504</a> <a href="#">Viruses. 2022 Sep 17;14(9):2069.</a> CROI 2020, <a href="#">Abstract 339</a> , <a href="#">Abstract 348LB</a> <a href="#">Lancet HIV 2020 Mar 9.</a> HIV Persistence Workshop 2019, <a href="#">Abstract OP 4.5</a> <a href="#">Nature. 2019 Apr;568(7751):244-248.</a> CROI 2019, <a href="#">Poster abstract 394</a> <a href="#">Ann Intern Med. 2018;169(10):674-683.</a>
Identification and quantification of HIV CNS latency biomarkers	<a href="#">NCT02989285</a>	St Vincent's Hospital, Sydney	N/A	December 2020 <a href="#">PNAS 119(48): e2210584119.</a>
Immuno-virological evaluation of persons living with HIV (PLWH)	<a href="#">NCT05973825</a> (not yet open for enrollment)	University Hospital, Ghent	N/A	July 2029

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 2. Current Observational Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
Investigation of the impact of inducible, replication-competent latent HIV-1 as an impediment to HIV/AIDS cure in the context of sustained viral suppression	<a href="#">NCT04938518</a>	Kenya Medical Research Institute	N/A	April 2022
<b>LAMIVIH</b> : Evolution of HIV reservoir, inflammation, and microbiota footprint of PLWH switching to long-acting injectable treatment	<a href="#">NCT05303337</a>	Hôpital Européen Marseille	N/A	March 2024
Long-term clinical, immunologic, and virologic profiles of children who received early treatment for HIV	<a href="#">NCT05154513</a>	IMPAACT	N/A	November 2027
<b>NOVA</b> : Netherlands cohort study on acute HIV infection	<a href="#">NCT05728996</a>	Prof. Jan Prins	N/A	August 2028
Observational post-intervention controller (PIC) destination cohort	<a href="#">NCT05985642</a>	AIDS Clinical Trials Group	N/A	September 2029
<b>PediacamNEG</b> : Negative serology in children with HIV treated early with ART	<a href="#">NCT06302933</a>	Inserm-ANRS	N/A	August 2025
Post analytic treatment interruption study	<a href="#">NCT02761200</a>	South East Asia Research Collaboration with Hawaii	N/A	March 2031
<b>PRIMO</b> (ANRS CO6): Primary infection cohort	<a href="#">NCT03148964</a>	Inserm-ANRS	N/A	September 2025 <a href="#">See supplemental references page</a>
Quantification of antisense HIV RNA	<a href="#">NCT05381844</a>	Institut National de la Santé Et de la Recherche Médicale, France	N/A	December 2024
<b>RESERVIH32</b> : Bioclinical evaluation of two biomarkers of aviremic HIV-1 in CD4 T cells of adults undergoing treatment	<a href="#">NCT03940521</a>	Centre Hospitalier Universitaire de Nîmes	N/A	September 2025
<b>Saturne-HIV</b> : Sequential analysis before and after treatment initiation to unravel the role of naturally occurring extracellular vesicles in HIV infection	<a href="#">NCT04653610</a>	University Hospital, Ghent	N/A	January 2027
<b>TatLat</b> : Development of a new family of HIV latency regulators (LRAs) targeting the Tat viral protein	<a href="#">NCT06441123</a> (not yet open for enrollment)	University Hospital, Montpellier	N/A	December 2025
The Gemini Study: Safety and survival of genetically modified white blood cells in HIV+ twins	<a href="#">NCT04799483</a> (closed to enrollment)	NIAID	N/A	January 2030

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 2. Current Observational Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated End Date/Interim Results
The Last Gift Study (for people with HIV and less than 6 months life expectancy due to terminal illness)	<a href="#">UCSD study website</a>	University of California, San Diego (UCSD)	N/A	N/A <a href="#">Strategies for an HIV Cure 2023, Abstracts PP22 &amp; PP73</a> <a href="#">J Virus Erad. 2023 Jun 5;9(2):100328.</a> <a href="#">Curr HIV/AIDS Rep. 2022 Oct 19;1-14.</a> <a href="#">J Med Ethics. 2022 Jun 22</a> <a href="#">PLoS One. 2021 May 7;16(5):e0250882.</a> <a href="#">J Clin Invest. 2020 Jan 7</a> HIV Persistence Workshop 2019, Abstract PP 5.7.5 (see <a href="#">abstract book</a> )
The role of the gastrointestinal-associated lymphoid tissue in the cure of HIV infection	<a href="#">NCT05652088</a> (enrolling by invitation)	Icahn School of Medicine at Mount Sinai	N/A	June 2025
The use of leukapheresis to support HIV pathogenesis studies	<a href="#">NCT01161199</a>	University of California, San Francisco	N/A	July 2033
Thinking and memory problems in people with HIV	<a href="#">NCT01875588</a>	National Institute of Neurological Disorders and Stroke (NINDS)	N/A	February 2037
<b>TRESAX:</b> T follicular helper reservoir in axillary lymph nodes study	<a href="#">hivcure.com.au</a> (no registry entry)	Kirby Institute	N/A	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>ADOPTIVE IMMUNOTHERAPY</b>				
Early ART in combination with autologous HIV-specific cytotoxic T lymphocyte (CTL) infusion	<a href="#">NCT02231281</a>	Yongtao Sun, MD, PhD, Tangdu Hospital, the Fourth Military Medical University	Phase III	N/A
Reconstitution of HIV-specific immunity against HIV	<a href="#">NCT02563509</a>	Guangzhou 8th People's Hospital	Phase I/II	N/A
HIV-specific memory CD8 T cells adoptive immunotherapy	<a href="#">ChiCTR-ICR-15005775</a>	Beijing You'an Hospital, Capital Medical University	Phase I	<a href="#">Front Immunol. 2019 Mar 18;10:437</a>
<b>HXTC:</b> HIV 1 antigen expanded specific T cell therapy	<a href="#">NCT02208167</a>	University of North Carolina, Chapel Hill	Phase I	<a href="#">Mol Ther. 2018 Oct 3;26(10):2496-2506.</a>
<b>ANALYTICAL TREATMENT INTERRUPTION</b>				
<b>TESOVIR:</b> Tracking and exploring the source of viral rebound	<a href="#">NCT03117985</a>	Centre Hospitalier Régional d'Orléans	N/A	Terminated (no interesting results)
<b>ANTIBODIES</b>				
<b>CHERUB 001:</b> IVIG in primary HIV infection	No clinicaltrials.gov entry	CHERUB	N/A	<a href="#">HIV Med. 2017 Jul 18.</a>
<b>VRC01</b> (analytical treatment interruption in AMP trial participants)	<a href="#">NCT04801758</a>	HIV Vaccine Trials Network	N/A	N/A
<b>GSK3810109A</b> (broadly neutralizing antibody formerly named N6-LS)	<a href="#">NCT04871113</a>	ViiV Healthcare	Phase IIa	EACS 2023, Abstracts <a href="#">PS8.O5</a> & <a href="#">eP.A.099</a> CROI 2023, <a href="#">Abstract 520</a> HIV Glasgow 2022, <a href="#">Abstract O34</a>
<b>3BNC117</b> (broadly neutralizing monoclonal antibody)	<a href="#">NCT02446847</a>	Rockefeller University	Phase II	<a href="#">Nature. 2016 Jul 28; 535(7613):556–560</a>
<b>3BNC117</b>	<a href="#">NCT02588586</a>	Rockefeller University	Phase II	<a href="#">J Exp Med. 215(9):2311-2324.</a>
<b>UB-421</b> (antibody inhibitor of HIV binding to CD4 receptors)	<a href="#">NCT03743376</a>	United BioPharma	Phase II	N/A
<b>UB-421</b>	<a href="#">NCT02369146</a>	United BioPharma	Phase II	<a href="#">N Engl J Med. 2019;380(16):1535-45</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)



**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>ANTIBODIES (Cont.)</b>				
<b>vedolizumab</b> (anti- $\alpha_4\beta_7$ integrin antibody)	<a href="#">NCT03577782</a>	Hospitales Universitarios Virgen del Rocío	Phase II	<a href="#">JCI Insight. e182312.</a> CROI 2022, <a href="#">Abstract 359</a> XI Congreso Nacional GeSIDA, Abstract PO-48 ( <a href="#">video</a> )
<b>VRC01</b> (broadly neutralizing monoclonal antibody)	<a href="#">NCT02664415</a>	National Institute of Allergy and Infectious Diseases (NIAID)	Phase II	<a href="#">J Clin Invest. 130(6):3299-3304.</a> <a href="#">Lancet HIV. 2019 May;6(5):e297-e306.</a> IAS 2017, Abstract <a href="#">TUAB0106LB</a> ( <a href="#">slides</a> , <a href="#">video</a> )
<b>PGT121 + VRC07-523LS +/- PGDM1400</b> (broadly neutralizing antibodies)	<a href="#">NCT03721510</a>	International AIDS Vaccine Initiative	Phase I/IIa	<a href="#">Nat Med. 2024 Sep 12.</a> CROI 2024, Abstracts <a href="#">121</a> , <a href="#">483</a>
<b>VRC01</b> (broadly neutralizing antibody) in infants	<a href="#">NCT03208231</a>	NIAID	Phase I/II	AIDS 2022, <a href="#">Abstract OALBB0102</a>
<b>VRC01LS + 10-1074</b> (broadly neutralizing antibodies) in early-treated children	<a href="#">NCT03707977</a>	NIAID	Phase I/II	<a href="#">Sci Transl Med. 2023 15(703):eadh0004.</a> CROI 2023, Abstracts <a href="#">141</a> , <a href="#">828</a> <a href="#">JAIDS. 2022 Oct 1;91(2):182-188.</a> CROI 2022, <a href="#">Abstract 32</a> CROI 2021, <a href="#">Abstract 609</a> , <a href="#">Webcast</a>
<b>ABBV-382</b> (anti- $\alpha_4\beta_7$ integrin antibody)	<a href="#">NCT04554966</a>	AbbVie	Phase Ib	N/A
<b>10-1074</b> (broadly neutralizing monoclonal antibody)	<a href="#">NCT02511990</a>	Rockefeller University	Phase I	<a href="#">Nat Med. 2017 Feb;23(2):185-191</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>ANTIBODIES (Cont.)</b>				
<b>10-1074-LS + 3BNC117-LS</b> (long-acting broadly neutralizing antibodies)	<a href="#">NCT03554408</a>	Rockefeller University	Phase I	N/A
<b>3BNC117</b>	<a href="#">NCT02018510</a>	Rockefeller University	Phase I	<a href="#">Nature. 2015 Jun 25;522(7557):487-91</a>
<b>3BNC117 + 10-1074</b>	<a href="#">NCT03571204</a>	NIAID	Phase I	<a href="#">Nature. 2022 Jun; 606(7913):375-381.</a>
<b>3BNC117 + 10-1074</b>	<a href="#">NCT02825797</a>	Rockefeller University	Phase I	<a href="#">Nat Med. 2020 Feb;26(2):222-227</a> <a href="#">Nature. 2018 Sep;561:479-484.</a> <a href="#">Nat Med. 2018 Sep 26.</a>
<b>3BNC117 + 10-1074</b>	<a href="#">NCT03526848</a>	Rockefeller University	Phase I	<a href="#">Nature. 2022 Apr 13</a> CROI 2022, <a href="#">Abstract 361</a>
<b>3BNC117-LS + 10-1074-LS</b> in viremic HIV+ individuals	<a href="#">NCT04250636</a>	Rockefeller University	Phase I	CROI 2022, <a href="#">Abstract 140</a>
<b>3BNC117-LS</b>	<a href="#">NCT03254277</a>	Rockefeller University	Phase I	N/A
<b>elipovimab</b> (formerly GS-9722; PGT121-derived broadly neutralizing antibody)	GS-US-420-3902 <a href="#">Adisinsight entry</a>	Gilead Sciences	Phase I	CROI 2022, <a href="#">Abstract 349</a> CROI 2020, <a href="#">Abstract 39</a> , <a href="#">Webcast</a>
<b>PGDM1400 +/- PGT121 +/- VRC07-523LS</b> (broadly neutralizing antibodies)	<a href="#">NCT03205917</a>	International AIDS Vaccine Initiative	Phase I	<a href="#">Nat Med 2022 May 12</a> CROI 2022, <a href="#">Abstract 139</a>
<b>PGT121</b>	<a href="#">NCT02960581</a>	International AIDS Vaccine Initiative	Phase I	<a href="#">Nat Med. 2021 Oct 7.</a> CROI 2019, <a href="#">Abstract 145</a> , <a href="#">Webcast</a>
<b>SAR441236</b> (tri-specific broadly neutralizing antibody)	<a href="#">NCT03705169</a>	NIAID	Phase I	CROI 2024, <a href="#">Abstract 118</a> <a href="#">Results posted in clinicaltrials.gov</a>
<b>vedolizumab</b>	<a href="#">NCT02788175</a>	NIAID	Phase I	<a href="#">Sci Transl Med. 11(509):eaax3447.</a> AIDS 2018, <a href="#">WESS0102</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>ANTIBODIES (Cont.)</b>				
VRC01 + 10-1074	<a href="#">NCT03831945</a>	NIAID	Phase I	Terminated: unable to recruit due to COVID
VRC01 in acute HIV infection	<a href="#">NCT02591420</a>	NIAID	Phase I	CROI 2023, <a href="#">Abstract 430</a>
VRC01	<a href="#">NCT02411539</a>	NIAID	Phase I	<a href="#">OFID. 5(10):ofy242.</a>
VRC01	<a href="#">NCT02471326</a>	NIAID	Phase I	<a href="#">N Engl J Med. 2016 Nov 24;375(21):2037-2050</a>
VRC01	<a href="#">NCT02463227</a>	NIAID	Phase I	CROI 2023, <a href="#">Abstract 390</a> HIV Persistence Workshop 2022, <a href="#">Abstract PP 4.10 (slides)</a> <a href="#">N Engl J Med. 375(21):2037-2050</a> CROI 2016, Abstract 32LB, <a href="#">Webcast</a>
VRC01	<a href="#">NCT01950325</a>	NIAID	Phase I	<a href="#">Sci Transl Med. 7(319):319ra206</a>
VRC01LS, VRC07-523LS (long-acting broadly neutralizing antibodies)	<a href="#">NCT02840474</a>	NIAID	Phase I	IAS 2019, <a href="#">Abstract WEAA0305LB (video, at 45:36)</a>
<b>ANTI-CMV THERAPY</b>				
Ietermovir (Prevymis)	<a href="#">NCT04840199</a>	NIAID	Phase II	CROI 2024, <a href="#">Abstract 354</a>
<b>ANTI-FIBROTIC</b>				
ACE inhibitors	<a href="#">NCT01535235</a>	UCSF/amfAR	Phase IV	<a href="#">Pathog Immun. 2017;2(3):310-34.</a>
losartan	<a href="#">NCT01852942</a>	University of Minnesota	Phase II	CROI 2020, <a href="#">Abstract 277</a>
telmisartan	<a href="#">NCT01928927</a>	AIDS Clinical Trials Group	Phase II	CROI 2019, <a href="#">Abstract 395</a> <a href="#">J Infect Dis. 2018 217(11):1770-1781</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>ANTI-FIBROTIC (Cont.)</b>				
telmisartan	<a href="#">NCT02170246</a>	Yale University	Phase I	CROI 2019, <a href="#">Abstract 300</a>
<b>ANTI-INFLAMMATORY</b>				
canakinumab (IL-1 $\beta$ inhibitor)	<a href="#">NCT02272946</a>	University of California, San Francisco	Phase II	<a href="#">J Am Coll Cardiol. 72(22):2809-2811.</a> CROI 2017, <a href="#">Abstract 126, Webcast</a>
CD24Fc (human CD24 extracellular domain and human IgG1 Fc fusion protein)	<a href="#">NCT03960541</a>	Oncolmmune, Inc.	Phase II	"Terminated (Business Reasons)"
High dose vitamin D supplementation	<a href="#">NCT03426592</a>	University of Melbourne	Phase II	<a href="#">J Virus Erad. 2023 Aug 29;9(3):100345.</a> CROI 2022, <a href="#">Abstract 355</a>
Camu Camu ( <i>Myrciaria dubia</i> )	<a href="#">NCT04058392</a>	McGill University Health Centre	Phase I	N/A
CC-11050 (phosphodiesterase-4 inhibitor)	<a href="#">NCT02652546</a>	NIAID	Phase I	<a href="#">OFID. 6(6):ofz246.</a> AIDS 2018, <a href="#">Poster abstract LBPEB021</a>
<b>ANTI-PROLIFERATIVE</b>				
mycophenolate mofetil (MMF)	<a href="#">NCT03262441</a>	Fred Hutchinson Cancer Research Ctr	Phase I	<a href="#">OFID 2022, ofac620</a> CROI 2020, <a href="#">Abstract 340</a>
<b>ANTIRETROVIRAL THERAPY</b>				
dolutegravir in reservoirs	<a href="#">NCT02924389</a>	Emory University	Phase IV	<a href="#">AIDS. 2018 Sep 24;32(15):2151-2159.</a>
HIV reservoir dynamics after switching to dolutegravir in patients on a PI/r based regimen	<a href="#">NCT02513147</a>	Hospital Universitari Vall d'Hebron Research Institute	Phase IV	N/A
raltegravir or efavirenz + tenofovir + emtricitibine	<a href="#">NCT00734344</a>	University of Alabama at Birmingham	Phase IV	N/A
doravirine concentrations and antiviral activity in cerebrospinal fluid	<a href="#">NCT04079452</a>	Fundacio Lluita Contra la SIDA	Phase III	<a href="#">Clin Infect Dis. 2021 Sep 21;ciab835.</a>
IDOLTIB: Impact of dolutegravir + lamivudine simplification on HIV-1 reservoirs	<a href="#">NCT04034862</a>	University of Liege	Phase III	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>ANTIRETROVIRAL THERAPY (Cont.)</b>				
ABX464	<a href="#">NCT02735863</a>	Abivax S.A.	Phase II	<a href="#">J. Virus Eradication 2019;5:10–22</a>
ABX464	<a href="#">NCT02990325</a>	Abivax S.A.	Phase I/II	<a href="#">J Infect Dis. jiad251.</a> <a href="#">Clin Infect Dis. 2021 Aug 26:ciab733.</a> CROI 2020, <a href="#">Abstract 335</a> HIV Persistence Workshop 2019, <a href="#">Abstract OP 8.3</a>
<b>ANTIRETROVIRAL THERAPY IN HIV CONTROLLERS</b>				
emtricitabine + rilpivirine + tenofovir	<a href="#">NCT01777997</a>	AIDS Clinical Trials Group/NIAID	Phase IV	<a href="#">J Infect Dis. 2020 June 4:jiaa294</a> <a href="#">Clin Infect Dis. 2019 May 25.</a> CROI 2019, <a href="#">Poster abstract 508</a> CROI 2018, <a href="#">Poster abstract 229</a>
raltegravir + tenofovir + emtricitabine	<a href="#">NCT01025427</a>	University of California, San Francisco	Phase IV	<a href="#">PLoS Pathog. 2013;9(10):e1003691</a>
<b>ASSEMBLY INHIBITORS</b>				
BIT225	<a href="#">ACTRN12617000025336</a>	Biotron Limited	Phase II	<a href="#">J Infect Dis. 2021 Jun 4;223(11):1914-1922.</a> CROI 2020, <a href="#">Abstract 506</a> <a href="#">HIV DART 2018</a>
BIT225	<a href="#">ACTRN12612000696897</a>	Biotron Limited	Phase I	<a href="#">JAC. 2016 Mar;71(3):731-8</a>
<b>CANNABINOIDS</b>				
<b>GALIG-CBD:</b> Effects of cannabidiol on the activation of autophagy and inflammation genes	<a href="#">NCT05306249</a>	Centre Hospitalier Régional d'Orléans	Phase II	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>CANNABINOIDS (Cont.)</b>				
TN-TC11M2, TN-C200M2 oral capsules	<a href="#">NCT03550352</a>	McGill University Health Center	Phase II	<a href="#">J Pers Med.14(7):745.</a> IAS 2023, <a href="#">Abstract EPB0270</a> <a href="#">Cells. 12(14):1811.</a> <a href="#">Biomedicines. 10(12):3168.</a>
<b>COMBINATIONS</b>				
maraviroc, dolutegravir, dendritic cell vaccine, auranofin, nicotinamide	<a href="#">NCT02961829</a>	Federal University of São Paulo	Not listed	CROI 2023, <a href="#">Abstract 383</a> CROI 2021, <a href="#">Abstract 313</a> <a href="#">AIDS Res Ther. 2022 Jan 12;19(1):2.</a> AIDS 2020, <a href="#">Abstract OAXLB0105</a> HIV Persistence Workshop 2019, <a href="#">Abstract OP 8.6</a> <a href="#">Int J Antimicrob Agents. pii: S0924-8579(19)30212-2.</a> CROI 2019, <a href="#">Poster abstract 399</a> AIDS 2018, Abstract WEPDB0105 ( <a href="#">slides</a> , <a href="#">video</a> )
<b>Perturbing of HIV reservoir with immune stimulation:</b> Fluarix, Pneumovax vaccines	<a href="#">NCT02707692</a>	University of California, San Diego	Not listed	<a href="#">AIDS. 2024 Mar 25.</a> CROI 2022, <a href="#">Abstract 358</a>
<b>ART +/- cyclosporine A, GM-CSF, pegylated interferon-alpha2b, IL-2</b>	<a href="#">NCT00979706</a>	Juan A. Arnaiz	Phase IV	<a href="#">Lancet HIV. 10(1):e42-e51.</a> AIDS 2022, <a href="#">Abstract OAA0205</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>COMBINATIONS (Cont.)</b>				
<b>MVA.HTI + ChAdOx1.HTI</b> therapeutic vaccines + <b>vesatolimod</b> (TLR7 agonist)	<a href="#">NCT04364035</a>	Aelix Therapeutics	Phase IIa	CROI 2023, <a href="#">Abstract 433</a> HIV Persistence Workshop 2022, <a href="#">Abstract PP 7.4</a>
<b>ROADMAP:</b> romidepsin + 3BNC117	<a href="#">NCT02850016</a>	Rockefeller University	Phase IIa	<a href="#">Lancet Microbe. 2022 Mar;3(3):e203-e214</a> CROI 2020, <a href="#">Abstract 38</a> , <a href="#">Webcast</a>
<b>TITAN:</b> lefitolimod + 3BNC117 + 10-1074 (TLR9 agonist + broadly neutralizing antibodies)	<a href="#">NCT03837756</a>	University of Aarhus	Phase IIa	<a href="#">Nat Med. 2023 Sep 11</a> CROI 2023, <a href="#">Abstract 136</a>
Adoptive transfer of <b>haploidentical natural killer cells</b> and <b>IL-2</b>	<a href="#">NCT03346499</a>	University of Minnesota - Clinical and Translational Science Institute	Phase II	<a href="#">J Infect Dis. 2024 Jan 11:jia578</a>
<b>Albuvirtide</b> (fusion inhibitor) + <b>3BNC117</b>	<a href="#">NCT04819347</a>	Frontier Biotechnologies Inc.	Phase II	N/A, unknown if study opened
<b>ASC22</b> (anti-PD-L1 antibody) + <b>chidamide</b> (HDAC inhibitor)	<a href="#">NCT05129189</a>	Shanghai Public Health Clinical Center	Phase II	<a href="#">Signal Transduct Target Ther. 9(1):231</a> , IAS 2023, <a href="#">Abstract LBEPB18</a>
<b>eCLEAR:</b> romidepsin + 3BNC117	<a href="#">NCT03041012</a>	Aarhus University Hospital	Phase II	CROI 2024, <a href="#">Abstract 486</a> HIV Persistence Workshop 2022, <a href="#">Abstract OP 1.9 (slides)</a> <a href="#">Nat Med. 2022 Oct 17</a> CROI 2022, <a href="#">Abstract 62</a> , <a href="#">Abstract 122</a>
<b>ERAMUNE-01</b> (antiretroviral intensification +/- interleukin-7)	<a href="#">NCT01019551</a>	ORVACS/Cytheris SA/Merck Sharp & Dohme Corp./Pfizer	Phase II	<a href="#">AIDS. 2016 Jan;30(2):221-30</a>
<b>ERAMUNE-02</b> (DNA/Ad5 vaccine, ART intensification)	<a href="#">NCT00976404</a>	Vical/GenVec/CHERUB/NIH Vaccine Research Center/ORVACS	Phase II	<a href="#">Lancet HIV. 2015 Mar;2(3):e82-91</a> CROI 2014, <a href="#">Poster abstract 422</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure September 16, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>COMBINATIONS (Cont.)</b>				
<b>MVA HIV-B +/- vedolizumab</b> (viral vector vaccine +/- anti- $\alpha_4\beta_7$ integrin antibody)	<a href="#">NCT04120415</a>	ANRS	Phase II	Stopped due to logistical issues
<b>Research in Viral Eradication of HIV Reservoirs (RIVER):</b> ART, ChAdV63.HIVconsv & MVA.HIVconsv vaccines, vorinostat	<a href="#">NCT02336074</a>	Imperial College London	Phase II	CROI 2024, <a href="#">Abstract 504</a> <a href="#">Sci Rep. 13(1):17155.</a> <a href="#">J Virus Erad. 2021 Sep 14; 7(3):100056.</a> <a href="#">Lancet. 395 (10227):888-898</a> AIDS 2018, Abstract TUAA0202LB ( <a href="#">slides</a> , <a href="#">video</a> )
<b>UB-421 + chidamide</b>	<a href="#">NCT05056974</a>	United BioPharma	Phase II	N/A
<b>vorinostat +/- tamoxifen</b> in postmenopausal women	<a href="#">NCT03382834</a>	NIAID	Phase II	<a href="#">Clin Infect Dis. 2022 Feb 17:ciac136.</a> CROI 2020, <a href="#">Abstract 333</a> , <a href="#">Webcast</a> HIV Persistence Workshop 2019, <a href="#">Abstract OP 3.2</a>
<b>disulfiram + vorinostat</b>	<a href="#">NCT03198559</a> (suspended due to neurotoxicity)	The Peter Doherty Institute for Infection and Immunity	Phase I/II	<a href="#">AIDS. 2021 Sep 29.</a> CROI 2019, <a href="#">Abstract 401</a>
<b>GTU-MultiHIV B-clade + MVA HIV-B +/- vedolizumab</b> (DNA + viral vector vaccines +/- anti- $\alpha_4\beta_7$ integrin antibody)	<a href="#">NCT02972450</a>	Inserm-ANRS	Phase I/II	Terminated due to bankruptcy of FITBiotech
<b>panobinostat + pegylated interferon-alpha2a</b>	<a href="#">NCT02471430</a>	Massachusetts General Hospital	Phase I/II	<a href="#">Cell. 187(5):1238-1254.e14.</a> CROI 2022, <a href="#">Abstract 357</a> CROI 2020, <a href="#">Abstract 341</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)



**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>COMBINATIONS (Cont.)</b>				
<b>Vacc-4x</b> (peptide-based therapeutic vaccine) + <b>romidepsin</b>	<a href="#">NCT02092116</a>	Bionor Immuno AS/Celgene	Phase I/II	CROI 2023, <a href="#">Abstract 337</a> CROI 2019, <a href="#">Abstract 397</a> <a href="#">Lancet HIV. 2016 Oct;3(10):e463-72</a>
<b>Vacc-4x + lenalidomide</b>	<a href="#">NCT01704781</a>	Bionor Immuno AS	Phase I/II	<a href="#">Results posted in clinicaltrials.gov</a>
<b>vorinostat + hydroxychloroquine + maraviroc (VHM)</b>	<a href="#">NCT02475915</a> <a href="#">NCT02470351</a> (CNS substudy)	South East Asia Research Collaboration with Hawaii	Phase I/II	<a href="#">J Virus Erad. 2020 (6) 100004</a> AIDS 2016, <a href="#">Abstract TUAX0101LB</a>
<b>elipovimab</b> (formerly GS-9722) +/- <b>vesatolimod</b>	<a href="#">GS-US-420-3902</a> (#18 on list, no clinicaltrials.gov entry)	Gilead Sciences	Phase Ib	N/A, elipovimab discontinued (see <a href="#">Adis Insight</a> )
Adoptive transfer of <b>haploidentical NK cells</b> and <b>N-803</b>	<a href="#">NCT03899480</a>	University of Minnesota - Clinical and Translational Science Institute	Phase I	<a href="#">J Infect Dis. 2024 Jan 11;jiad578</a>
<b>AGS-004 + vorinostat</b>	<a href="#">NCT02707900</a>	NIAID	Phase I	<a href="#">Sci Rep. 10(1):5134</a> . IAS 2019, <a href="#">Poster abstract MOPEB272</a>
<b>CD4-ZETA</b> gene-modified T cells +/- interleukin-2 (IL-2)	<a href="#">NCT01013415</a>	University of Pennsylvania	Phase I	CROI 2020, <a href="#">Abstract 337</a> , <a href="#">Webcast Mol Ther. 5(6):788-97</a>
<b>chemotherapy + maraviroc</b> in people with non-Hodgkin lymphoma	<a href="#">NCT02486510</a>	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Phase I	Terminated due to futility criteria
<b>Chidamide + CAR-T or TCR-T cell therapy</b>	<a href="#">NCT03980691</a>	Guangzhou 8th People's Hospital	Phase I	<a href="#">Cell Discov. 10(1):49</a> .
<b>DCV3</b> (dendritic cell-based vaccine pulsed with autologous inactivated HIV) + pegylated interferon	<a href="#">NCT02767193</a>	Judit Pich Martínez, Fundació Clínic per la Recerca Biomèdica	Phase I	<a href="#">Front Immunol. 2021 Nov 11;12:767370</a> . CROI 2020, <a href="#">Abstract 282</a> <a href="#">J Infect Dis. 2020; 221(10):1740-1742</a> .
<b>MVA-B</b> (viral vector vaccine) +/- <b>disulfiram</b>	<a href="#">NCT01571466</a>	Hospital Clinic of Barcelona/HIVACAT	Phase I	<a href="#">PLoS One. 2015 Nov 6;10(11):e0141456</a> . <a href="#">JAC. pii: dkv046</a> .

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>COMBINATIONS (Cont.)</b>				
MVA.HIVconsv + romidepsin	<a href="#">NCT02616874</a>	IrsiCaixa	Phase I	<a href="#">EBioMedicine. 95:104732.</a> CROI 2023, Abstracts <a href="#">385</a> , <a href="#">481</a> <a href="#">Microbiome. 10(1):59.</a> <a href="#">EBioMedicine. 78:103956.</a> <a href="#">AIDS. 2021 Nov 3</a> <a href="#">JAC. dkaa523.</a> <a href="#">Front Immunol. 11:823.</a> CROI 2019, <a href="#">Abstract 438</a> CROI 2017, <a href="#">Abstract 119LB</a> , <a href="#">Webcast</a>
peginterferon alfa-2b + 3BNC117 + 10-1074 (BEAT-2)	<a href="#">NCT03588715</a>	Wistar Institute	Phase I	CROI 2024, Abstracts <a href="#">179</a> , <a href="#">511</a> , <a href="#">1091</a> , <a href="#">1106</a> <a href="#">HIV Res Clin Pract. 24(1):2267825.</a> CROI 2023, Abstracts <a href="#">319</a> , <a href="#">326</a> , <a href="#">384</a> , <a href="#">431</a> HIV Persistence Workshop 2022, <a href="#">Abstracts PP 7.2, 8.10</a> CROI 2022, <a href="#">Abstract 352</a>
vorinostat + HXTC: HIV 1 antigen expanded specific T cell therapy	<a href="#">NCT03212989</a>	Julia Sung, MD, University of North Carolina, Chapel Hill	Phase I	<a href="#">J Infect Dis. jiad423.</a> IAS 2023, <a href="#">Abstract TUPEA02</a>
VRC07-523LS + vorinostat	<a href="#">NCT03803605</a>	University of North Carolina, Chapel Hill	Phase I	<a href="#">J Infect Dis. jiab487.</a> IAS 2021, <a href="#">Abstract OALA01LB03 (video)</a>
<b>CYTOKINES</b>				
interleukin-2 (IL-2)	<a href="#">NCT03308786</a>	Case Western Reserve University	Phase II	HIV Persistence Workshop 2022, <a href="#">Abstract OP 8.2 (slides)</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>CYTOKINES (Cont.)</b>				
Effect of <b>N-803</b> on B cell follicles	<a href="#">NCT04808908</a>	University of Minnesota	Phase I	N/A
<b>N-803</b>	<a href="#">NCT02191098</a>	University of Minnesota - Clinical and Translational Science Institute	Phase I	<a href="#">Nat Med. 2022 Jan 31.</a> <a href="#">CROI 2018, Poster abstract 356</a>
<b>DUAL-AFFINITY RE-TARGETING (DART) MOLECULES</b>				
<b>MGD020 +/- MGD014</b>	<a href="#">NCT05261191</a>	MacroGenics	Phase I	N/A
<b>MGD014</b>	<a href="#">NCT03570918</a>	MacroGenics	Phase I	AIDS 2022, <a href="#">Abstract OAA0403</a> <a href="#">Results posted in clinicaltrials.gov</a>
<b>GENE THERAPIES</b>				
<b>OZ1</b>	<a href="#">NCT00074997</a>	Janssen-Cilag Pty Ltd	Phase II	<a href="#">Nat Med. 2009 Mar; 15(3): 285–292.</a>
<b>Cal-1: Dual anti-HIV gene transfer construct</b>	<a href="#">NCT01734850</a>	Calimmune	Phase I/II	<a href="#">Results posted in clinicaltrials.gov</a>
<b>SB-728mR-T</b> (autologous CD4 T cells genetically modified at the CCR5 gene) + cyclophosphamide	<a href="#">NCT02225665</a>	Sangamo BioSciences	Phase I/II	N/A
<b>SB-728-T</b> + cyclophosphamide	<a href="#">NCT01543152</a>	Sangamo BioSciences	Phase I/II	CROI 2023, <a href="#">Abstract 182</a> <a href="#">bioRxiv 2021.02.28</a> CROI 2016, <a href="#">Poster abstract 358LB</a> CROI 2015, <a href="#">Poster abstract 434</a> CROI 2014, <a href="#">Abstract 141, Webcast</a>
<b>SB-728-T</b>	<a href="#">NCT01252641</a>	Sangamo BioSciences	Phase I/II	N/A
<b>SB-728-T</b>	<a href="#">NCT03666871</a>	Case Western Reserve University	Phase I/II	N/A
<b>VRX496</b> (gene-modified autologous CD4 T cells)	<a href="#">NCT00295477</a>	University of Pennsylvania	Phase I/II	<a href="#">Blood. 2013 Feb 28; 121(9): 1524–1533</a>
<b>AGT103-T</b> (gene-modified HIV-specific CD4 T cells)	<a href="#">NCT04561258</a>	American Gene Technologies International Inc.	Phase I	<a href="#">Front Med 2022 9:1044713.</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>GENE THERAPIES (Cont.)</b>				
<b>C34-CXCR4</b> (autologous CD4 T cells gene-modified to express HIV-inhibiting C34 peptide)	<a href="#">NCT03020524</a>	University of Pennsylvania	Phase I	N/A
<b>HGTV43</b>	No clinicaltrials.gov entry	Enzo Biochem	Phase I	AIDS 2006, <a href="#">Abstract MOPDA06</a>
Long-term follow-up of HIV+ participants exposed to <b>SB-728-T</b> or <b>SB-728mR-T</b>	<a href="#">NCT04201782</a>	Sangamo Therapeutics	Phase I	<a href="#">No significant safety issues</a>
<b>MazF-T</b> (redirected MazF-CD4 autologous T cells)	<a href="#">NCT01787994</a>	Takara Bio/University of Pennsylvania	Phase I	<a href="#">Mol Ther 2020 Nov 10</a> <a href="#">CROI 2015, Poster abstract 402</a>
Redirected high affinity Gag-specific T cells	<a href="#">NCT00991224</a>	University of Pennsylvania/Adaptimmune	Phase I	Study closed (safety): <a href="#">Mol Ther. 2015 Jul; 23(7): 1149–1159.</a>
<b>SB-728mR-T</b> + cyclophosphamide	<a href="#">NCT02388594</a>	University of Pennsylvania	Phase I	<a href="#">J Clin Invest. 2021.</a> <a href="#">CROI 2019, Abstract 25, Webcast</a>
<b>SB-728-T</b>	<a href="#">NCT01044654</a>	Sangamo BioSciences	Phase I	<a href="#">CROI 2023, Abstract 182</a> <a href="#">bioRxiv 2021.02.28</a> <a href="#">ICAAC 2014, Abstract H-643; ICAAC 2013, Abstract H-1464c</a>
<b>SB-728-T</b>	<a href="#">NCT00842634</a>	Sangamo Biosciences/University of Pennsylvania	Phase I	<a href="#">N Engl J Med. 2014 Mar 6;370(10):901–10</a>
shRNA-modified CD34+ cells	<a href="#">NCT03517631</a>	Shanghai Public Health Clinical Center	Phase I	N/A
<b>TCTIWHI</b> : Third-generation CAR-T-cell therapy	<a href="#">NCT04863066</a>	Beijing 302 Hospital	Phase I	N/A
<b>GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS</b>				
CRISPR CCR5 modified CD34+ cells	<a href="#">NCT03164135</a>	307 Hospital of PLA (Affiliated Hospital of Academy to Military Medical Sciences)	Not listed	<a href="#">N Engl J Med. 2019 Sep 11</a>
Stem cells gene-modified with M87o vector encoding HIV-inhibiting C46 peptide	<a href="#">NCT00858793</a>	Universitätsklinikum Hamburg-Eppendorf	Phase I/II	N/A
Stem cells gene-modified with <b>Cal-1</b>	<a href="#">NCT03593187</a>	Assistance Publique - Hôpitaux de Paris	Phase I/II	<a href="#">Mol Ther Methods Clin Dev. 2019;13:303-309</a>
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)	<a href="#">NCT00569985</a>	City of Hope Medical Center	Phase I	<a href="#">Sci Transl Med. 2010 Jun 16; 2(36): 36ra43.</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>GONADOTROPIN-RELEASING HORMONE (GnRH) AGONISTS</b>				
triptorelin acetate depot	<a href="#">NCT03536234</a>	Immune System Regulation AB	Phase II	N/A
<b>HORMONES</b>				
<b>somatotropin</b> (human growth hormone)	<a href="#">NCT03091374</a>	McGill University Health Center	Phase II	CROI 2021, <a href="#">Abstract 298</a> , <a href="#">Webcast</a>
<b>IMAGING STUDIES</b>				
123I radiolabeled 3BNC117	<a href="#">NCT03468582</a>	University of Lausanne Hospitals	Phase I	N/A
Radiolabeled 3BNC117 + Copper-64 radio isotope followed by MRI/PET scanning to detect HIV in vivo	<a href="#">NCT03063788</a>	Bayside Health	Phase I	<a href="#">EBioMedicine. 2021 Feb 25;65:103252.</a> AIDS 2020, <a href="#">Abstract PEA0060</a>
<b>IMMUNE CHECKPOINT INHIBITORS</b>				
<b>durvalumab</b> (anti-PD-L1 antibody) in solid tumors	<a href="#">NCT03094286</a>	Spanish Lung Cancer Group	Phase II	ESMO 2020, <a href="#">Abstract 1275P</a> <a href="#">JAMA Oncol. 2020 Jul 1;6(7):1063-1067</a>
<b>cemiplimab</b> (anti-PD-1 antibody)	<a href="#">NCT03787095</a>	NIAID	Phase I/II	<a href="#">OFID 11(3):ofad694.</a> <a href="#">JAIDS. 87(5):e234-e236.</a> 2020 Community HIV Cure Research Workshop ( <a href="#">slides</a> , <a href="#">video</a> ) <a href="#">ACTG announcement</a>
<b>budigalimab</b> (anti-PD-1 antibody)	<a href="#">NCT04223804</a>	AbbVie	Phase Ib	CROI 2024, <a href="#">Abstract 106</a> EACS 2023, <a href="#">Abstract PS10.O3</a>
<b>BMS-936559</b> (anti-PD-L1 antibody)	<a href="#">NCT02028403</a>	National Institute of Allergy and Infectious Diseases (NIAID)	Phase I	<a href="#">J Infect Dis. 2017 Jun 1;215(11):1725-1733</a> CROI 2016, <a href="#">Abstract 25</a> , <a href="#">Webcast</a>
<b>budigalimab</b> (anti-PD-1 antibody)	<a href="#">NCT04799353</a>	AbbVie	Phase I	EACS 2023, <a href="#">Abstract PS10.O3</a>
<b>ipilimumab</b> (anti-CTLA-4 antibody)	<a href="#">NCT03407105</a>	Medarex	Phase I	<a href="#">PLoS One. 2018 Jun 7;13(6):e0198158</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>IMMUNE CHECKPOINT INHIBITORS (Cont.)</b>				
<b>pembrolizumab</b> (anti-PD-1 antibody) in treating patients with HIV and relapsed, refractory, or disseminated malignant neoplasms	<a href="#">NCT02595866</a>	National Cancer Institute (NCI)	Phase I	CROI 2023, <a href="#">Abstract 181 Sci Transl Med. 14(629):eabl3836</a> <a href="#">JAMA Oncol. Sep 1;5(9):1332-1339</a> CROI 2019, <a href="#">Abstract 27</a> CROI 2018, <a href="#">Abstract 656LB</a>
<b>pembrolizumab</b> (anti-PD-1 antibody) single dose	<a href="#">NCT03239899</a>	National Institute of Neurological Disorders and Stroke (NINDS)	Phase I	HIV Persistence Workshop 2022, <a href="#">Abstract OP 1.10 (slides)</a>
<b>IRON CHELATORS</b>				
<b>deferiprone</b>	<a href="#">NCT02456558</a>	ApoPharma	Phase I	N/A
<b>JANUS KINASE INHIBITORS</b>				
<b>ruxolitinib</b>	<a href="#">NCT02475655</a>	NIAID	Phase II	CROI 2024, <a href="#">Abstract 521</a> IAS 2023, <a href="#">Abstract TUPEB15</a> <a href="#">J Clin Pharmacol. 2021 Jun 24.</a> <a href="#">Clin Infect Dis. 2021</a> CROI 2019, <a href="#">Abstract 37</a>
<b>LATENCY-REVERSING AGENTS</b>				
<b>disulfiram</b> (acetaldehyde dehydrogenase inhibitor)	<a href="#">NCT01286259</a>	University of California, San Francisco/ Johns Hopkins University/amfAR	Not specified	<a href="#">Clin Infect Dis. 2014 58 (6): 883–90</a>
<b>Chidamide</b>	<a href="#">NCT02902185</a>	Tang-Du Hospital	Phase II/III	N/A
<b>vorinostat</b> (HDAC inhibitor)	<a href="#">NCT01365065</a>	Bayside Health/Merck	Phase II	<a href="#">PLoS Pathog. 2014;10(10):e1004473</a>
<b>valproic acid</b> (HDAC inhibitor)	<a href="#">NCT00289952</a>	McGill University	Phase II	<a href="#">HIV Med. 2012 May;13(5):291–6</a>
<b>valproic acid</b>	<a href="#">NCT00614458</a>	University of North Carolina at Chapel Hill/NIAID/Abbott/Merck Sharp & Dohme	Phase II	<a href="#">PLoS One. 2010 5(2): e9390</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/ Presented Data
<b>LATENCY-REVERSING AGENTS (Cont.)</b>				
<b>Chidamide</b> (HDAC inhibitor)	<a href="#">NCT02513901</a>	Tang-Du Hospital	Phase I/II	<a href="#">HIV Med. 2020 Dec;21(11):747-757.</a> AIDS 2018, Abstract WEAA0101 ( <a href="#">slides</a> , <a href="#">video</a> )
<b>disulfiram</b>	<a href="#">NCT01944371</a>	University of California, San Francisco/Monash University/amfAR	Phase I/II	CROI 2015, <a href="#">Poster abstract 428LB</a>
<b>panobinostat</b> (HDAC inhibitor)	<a href="#">NCT01680094</a>	University of Aarhus/Massachusetts General Hospital/Monash University/Karolinska Institutet/Novartis/amfAR	Phase I/II	CROI 2015, <a href="#">Abstract 109</a> , <a href="#">Webcast The Lancet HIV. 2014 Oct; 1(1): e13–e21</a>
<b>romidepsin</b> (HDAC inhibitor)	<a href="#">NCT01933594</a>	AIDS Clinical Trials Group/NIAID/Gilead	Phase I/II	<a href="#">JID, jiaa777</a> CROI 2019, <a href="#">Abstract 26</a> , <a href="#">Webcast</a> CROI 2018, <a href="#">Abstract 72</a> , <a href="#">Webcast</a>
<b>valproic acid + pyrimethamine</b>	<a href="#">NCT03525730</a>	Erasmus Medical Center	Phase I/II	<a href="#">Sci Adv. 2023 Mar 17;9(11):eade6675.</a>
<b>vorinostat</b>	<a href="#">NCT01319383</a>	University of North Carolina at Chapel Hill/NIAID/Merck.	Phase I/II	<a href="#">J Clin Invest. 2017 Aug 1;127(8):3126-3135.</a> <a href="#">J Infect Dis. 2014 Sep 1;210(5):728-35</a> <a href="#">Nature. 487(7408):482-5</a>
<b>bryostatin 1</b> (PKC agonist)	<a href="#">NCT02269605</a>	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Phase I	<a href="#">AIDS. 2016 Jun 1;30(9):1385-92.</a>
<b>Euphorbia kansui</b>	<a href="#">NCT04503928</a>	Shanghai Public Health Clinical Center	Phase I	N/A, unknown if study opened
<b>Kansui</b> (traditional Chinese medicine with ingenols)	<a href="#">NCT02531295</a>	UCSF	Phase I	Study terminated
<b>mTOR INHIBITORS</b>				
Impact of <b>Everolimus</b> on HIV persistence post kidney or liver transplant	<a href="#">NCT02429869</a>	UCSF	Phase IV	<a href="#">Am J Transplant. 21(5):1765-1779.</a>
<b>metformin</b>	<a href="#">NCT04500678</a>	University of Hawaii	Phase II/III	<a href="#">ARHR 36(4):303-305.</a> <a href="#">ARHR. 37(1):24-33.</a> <a href="#">Aging Cell 23(1):e13926.</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/ Presented Data
<b>mTOR INHIBITORS (Cont.)</b>				
<b>Sirolimus</b>	<a href="#">NCT02440789</a>	ACTG	Phase I/II	CROI 2019, <a href="#">Abstract 131</a> , <a href="#">Webcast</a>
<b>metformin</b>	<a href="#">NCT02659306</a>	McGill University Health Center	Phase I	<a href="#">EBioMedicine 65:103270</a> CROI 2020, <a href="#">Poster abstract 229</a> CROI 2019, <a href="#">Poster abstract 301</a>
<b>OBSERVATIONAL STUDIES</b>				
<b>2000HIV:</b> 2000 HIV human functional genomics partnership program	<a href="#">NCT03994835</a>	Radboud University	N/A	CROI 2024, Abstracts <a href="#">319</a> , <a href="#">442</a> , <a href="#">515</a> <a href="#">Front Immunol. 13:982746</a>
<b>2000HIVTrained:</b> 2000 HIV trained innate immunity in HIV elite controllers	<a href="#">NCT04968717</a>	Radboud University	N/A	CROI 2024, <a href="#">Abstract 442</a> CROI 2023, Abstracts <a href="#">313</a> , <a href="#">314</a>
<b>ACTG A5321:</b> Decay of HIV-1 reservoirs in subjects on long-term antiretroviral therapy: The ACTG HIV reservoirs cohort (AHRC) study	N/A	AIDS Clinical Trials Group	N/A	CROI 2023, Abstracts <a href="#">392</a> , <a href="#">398</a> <a href="#">J Infect Dis. jiad039</a> . HIV Persistence 2022, <a href="#">Abstract PP 7.8</a> <a href="#">AIDS. 2022 Jun 23. FCIM 12:757846</a> . <a href="#">J Infect Dis. 2022:jiac030</a> CROI 2021, <a href="#">Abstract 241</a> , <a href="#">Webcast</a> HIV Persistence 2019, Abstracts OP 4.6, 5.6 & PP 4.4 (see <a href="#">abstract book</a> ) <a href="#">JAIDS. 81(5):594-599</a> . CROI 2018, <a href="#">Abstract 119</a> , <a href="#">Webcast</a> <a href="#">Abstract 403LB</a> <a href="#">PLoS Pathog. 13(9):e1006629</a> . <a href="#">PLoS Pathog. 13(4): e1006285</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)



# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>OBSERVATIONAL STUDIES (Cont.)</b>				
<b>ANRS CO24 OncoVIHAC:</b> Immune checkpoint inhibitors in HIV+ individuals with cancers	<a href="#">NCT03354936</a>	Inserm-ANRS	N/A	<a href="#">Cells. 2022 Mar 17;11(6):1015.</a> <a href="#">AIDS 2020, Abstract OAB0203</a>
<b>ANRS EP 44:</b> Residual replication of HIV-1 in the gut associated lymphoid tissue (GALT)	<a href="#">NCT01038401</a>	Inserm-ANRS	N/A	N/A
<b>ANRS EP63:</b> A chronological study of the formation of HIV cellular reservoirs through the expression of surface markers on CD4+ T cell, inc. CD32a	<a href="#">NCT03298360</a>	Inserm-ANRS	N/A	N/A
<b>APACHE:</b> Monitored antiretroviral pause in chronically infected HIV+ individuals with long-lasting suppressed viremia	<a href="#">NCT03198325</a>	Ospedale San Raffaele	N/A	<a href="#">PLoS One. 2022 Mar 15;17(3):e0265348.</a> <a href="#">Viruses. 2021 Jul 19;13(7):1403.</a> <a href="#">AIDS: May 14, 2021</a> <a href="#">J Antimicrob Chemother. 2021 Mar 7:dkab060.</a> <a href="#">J Antimicrob Chemother. 2020 Jun 15:dkaa231.</a> <a href="#">HIV Persistence 2019, Abstract PP 5.7.10</a> <a href="#">J Antimicrob Chemother. 2019 April 23. pii: dkz138</a>
<b>ATN 147</b>	<a href="#">ATN Cares website</a>	The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)	N/A	CROI 2023, <a href="#">Abstract 457</a>
<b>AVIR:</b> Characterization of HIV-1 reservoirs in adolescents with non-B HIV-1 on ART in Cameroon	<a href="#">NCT06363500</a>	Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS	N/A	<a href="#">J Virus Erad. 10(1):100367.</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>OBSERVATIONAL STUDIES (Cont.)</b>				
Biomarkers to predict time to plasma HIV RNA rebound (ACTG A5345)	<a href="#">NCT03001128</a>	AIDS Clinical Trials Group	N/A	<a href="#">JCI Insight.9(3):e173864</a> CROI 2023, Abstracts <a href="#">337</a> , <a href="#">380</a> HIV Persistence Workshop 2022, <a href="#">Abstracts OP 7.3, PP 7.9 (slides)</a> <a href="#">ARHR. 38(6):510-517</a> CROI 2022, <a href="#">Abstract 379</a> <a href="#">Clin Infect Dis. 2021 Jun 12:ciab541.</a> CROI 2021, <a href="#">Abstract 311</a> , <a href="#">Webcast</a> AIDS 2020, <a href="#">Abstract PDB0102</a>
<b>CHERUB 003</b> (prospective HIV chemotherapy cohort study)	<a href="#">NCT01902693</a>	Imperial College London/CHERUB	N/A	N/A
<b>CLEAC</b> : Comparison of late versus early antiretroviral therapy in children with HIV	<a href="#">NCT02674867</a>	Inserm-ANRS	N/A	<a href="#">Front Immunol. 2021 Apr 22;12:662894.</a> <a href="#">Clin Infect Dis. ciaa1931</a> AIDS 2018, <a href="#">Abstract WEAB0208LB (slides)</a>
<b>DOLUVOIR</b> : Cartography of virologic reservoir related to antiretroviral concentrations in HIV-1+ patients on first line treatment containing dolutegravir	<a href="#">NCT04133012</a>	Inserm-ANRS	N/A	N/A
<b>EARTH</b> : Early antiretroviral treatment in children with HIV	<a href="#">NCT05784584</a>	PENTA Foundation	N/A	<a href="#">eClinicalMedicine, May 23, 2024</a>
Effects of dolutegravir based regimen on HIV-1 reservoir and immune activation	<a href="#">NCT02557997</a>	University Hospital, Strasbourg, France	N/A	<a href="#">J Antimicrob Chemother. 2017 Dec 13.</a>
<b>EPIC4</b> : Early Pediatric Initiation: Canada Child cure Cohort Study	<a href="#">CTN S 281</a>	Canadian Institutes of Health Research (CIHR)/Canadian Foundation for AIDS Research (CANFAR)/International AIDS Society (IAS)	N/A	<a href="#">AIDS. 34(5):687-697</a> <a href="#">Clin Infect Dis. pii: ciz251</a> AIDS 2014, <a href="#">Abstract TUAB0206LB (video)</a> <a href="#">Clin Infect Dis. (2014) 59 (7): 1012-1019.</a>
<b>EURECA</b> : Exploratory study of cellular reservoirs in blood	<a href="#">NCT02858414</a>	Centre Hospitalier Universitaire de Besancon	N/A	<a href="#">Viruses. 2018 Apr 13;10(4).</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/ Presented Data
<b>OBSERVATIONAL STUDIES (Cont.)</b>				
Expectation, motivation, and experience of HIV+ patients regarding participation to an HIV cure-related clinical trial (AMEP-EHVA T02)	<a href="#">NCT05280392</a>	ANRS	N/A	<a href="#">Abstract</a> , AIDS Impact 2023
<b>FXReservoir:</b> Study of the effects of farnesoid X receptor ligands on reactivation of latent provirus	<a href="#">NCT03618862</a>	Hospices Civils de Lyon	N/A	N/A
Genotyping FcγRs genes	<a href="#">NCT03130296</a>	University Hospital, Strasbourg, France	N/A	<a href="#">Genes Immun. 2020 Aug;21(4):263-268</a>
<b>HCURE:</b> Impact of HCV DAAs on antiviral immunity & HIV reservoir in HIV-HCV coinfection	<a href="#">NCT03244371</a>	Assistance Publique Hopitaux De Marseille	N/A	N/A
<b>HEATHER:</b> HIV reservoir targeting with early antiretroviral therapy	UK CPMS17589	University of Oxford/Medical Research Council/British HIV Association	N/A	<a href="#">Front Immunol. 2024 Mar 18;15:1352123.</a> <a href="#">Front Immunol. 2021; 12: 647688.</a> <a href="#">J Infect Dis. 2019 Nov 28. pii: jiz563</a> <a href="#">Mucosal Immunol. 2019 Sep;12(5):1212-1219.</a>
<b>HIV-PRADA:</b> HIV persistence in lymph node and peripheral blood	<a href="#">NCT03426189</a>	University of Melbourne	N/A	<a href="#">Cell Rep Med. 2022 Sep 28:100766</a> CROI 2021, <a href="#">Abstract 301</a> , <a href="#">Webcast</a>
HIV resistance and treatment strategies	<a href="#">NCT00581802</a>	NIAID	N/A	N/A
<b>HIV-STAR:</b> HIV sequencing after treatment interruption to identify the clinically relevant anatomical reservoir	<a href="#">NCT02641756</a>	University Hospital, Ghent	N/A	<a href="#">Cell Rep. 39(4):110739.</a> IAS 2021, <a href="#">Abstract PEA036 (poster, video)</a> <a href="#">J Virus Erad. 2021 Jan 23;7(1):100029.</a> CROI 2020, <a href="#">Abstract 324</a> <a href="#">Cell Host Microbe. 2019 Sep 11;26(3):347-358.e7.</a> AIDS 2018, Abstract <a href="#">WEAA0201 (slides, video)</a> , poster abstract <a href="#">THPEB096</a>
Host & viral factors associated with HIV elite control	UK CPMS16146	University College London Hospitals NHS Foundation Trust	N/A	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

## Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>OBSERVATIONAL STUDIES (Cont.)</b>				
<b>HSCT-HIV:</b> Allogeneic hematopoietic stem cell transplantation in HIV+ patients	<a href="#">NCT02732457</a>	Kirby Institute	N/A	Terminated by Protocol Steering Committee
<b>ImmunoCo27:</b> Co-adaptation between HIV and CD8 cellular immunity	<a href="#">NCT02886416</a>	Inserm-ANRS	N/A	N/A
<b>IMPAACT 2015:</b> Evaluation of the HIV-1 reservoir in the CNS of perinatally-infected youth and young adults with cognitive impairment	<a href="#">NCT03416790</a>	IMPAACT	N/A	<a href="#">AIDS. 2024 May 29.</a>
Impact of ART adherence on HIV persistence and inflammation	<a href="#">NCT02797093</a>	University of Colorado, Denver	N/A	N/A
Impact of a short-term ATI and re-initiation of antiretroviral therapy on immunologic and virologic parameters in HIV+ individuals	<a href="#">NCT03225118</a>	NIAID	N/A	<a href="#">J Infect Dis. 2020 May 22;jjaa270.</a>
In vitro autologous vaccine development to activate HIV reservoirs	UK CPMS17532	Imperial College London/amfAR	N/A	N/A
<b>ISALA:</b> Analytical treatment interruption	<a href="#">NCT02590354</a>	Institute of Tropical Medicine, Belgium	N/A	<a href="#">Strategies for an HIV Cure 2023, Abstract PP20</a> <a href="#">IAS 2023, Abstract TUPEA07</a> <a href="#">J Int AIDS Soc. 2020 Feb;23(2):e25453.</a> <a href="#">CROI 2019, Poster abstract 389, Webcast</a>
Long-term effects of ART in acute HIV infection	<a href="#">ChiCTR1800015006</a>	Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, The First Affiliated Hospital, China Medical University	N/A	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>OBSERVATIONAL STUDIES (Cont.)</b>				
<b>LoViReT:</b> Low viral reservoir treated patients	<a href="#">NCT02972931</a>	IrsiCaixa	N/A	HIV Persistence Workshop 2022, <a href="#">Abstract PP 3.13</a> <a href="#">J Intern Med. 2022 Mar 28.</a> <a href="#">EBioMedicine. 2020 Jun 21;57:102830.</a> CROI 2020, <a href="#">Abstract 374</a> HIV Persistence Workshop 2019, Abstract OP 3.5 (see <a href="#">abstract book</a> ) HIV Persistence Workshop 2017, <a href="#">Abstract OP 8.6</a>
Measurement for viral reservoir and immune function in HIV-1+ patients under antiretroviral therapy	<a href="#">NCT04068441</a>	National Taiwan University Hospital	N/A	<a href="#">JAIDS. 86(4):500-508</a>
<b>MUCOVIR:</b> Exploration of HIV reservoirs	<a href="#">NCT01019044</a>	Objectif Recherche Vaccins SIDA	N/A	<a href="#">JAIDS. 62(3):255–9</a>
<b>PembroHIV:</b> Treatment with immunological checkpoint inhibitors of HIV+ individuals with cancer	<a href="#">NCT03767465</a>	IrsiCaixa	N/A	HIV Persistence Workshop 2019, Abstract PP 4.2 (see <a href="#">abstract book</a> )
<b>PITCH:</b> Prospective interruption of therapy towards a cure for HIV pilot study	<a href="#">NHS Health Research Authority approval</a> (not entered into any online registry)	University of Oxford	N/A	<a href="#">Eur J Immunol. 2024 Aug 13:e2451200.</a> CROI 2022, <a href="#">Abstract 266</a> BHIVA Digital Conference, Nov 22–24, 2020, <a href="#">Abstract P22</a>
Quantitative measurement and correlates of the latent HIV reservoir in virally suppressed Ugandans	<a href="#">NCT02154035</a>	NIAID	N/A	<a href="#">EBioMedicine. 105040.</a> <a href="#">Virus Evol. 2023 Jul 27;9(2):vead046.</a> <a href="#">JCI Insight. 139287.</a> CROI 2020, <a href="#">Abstract 385</a> Persistence Workshop 2019, <a href="#">Abstract OP 7.4</a> <a href="#">Clin Infect Dis. 2017 Oct 15;65(8):1308-1315.</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>OBSERVATIONAL STUDIES (Cont.)</b>				
Role of anti-Tat immunity on disease progression in HIV+ asymptomatic adults	<a href="#">NCT01029548</a>	National HIV/AIDS Research Center (CNAIDS), Istituto Superiore di Sanità, Rome, Italy	N/A	<a href="#">Retrovirology. 2014 Jun 24;11:49.</a>
Role of anti-Tat immunity on disease progression in HIV+ cART-treated adults	<a href="#">NCT01024556</a>	CNAIDS, Istituto Superiore di Sanità, Rome, Italy	N/A	<a href="#">EBioMedicine 00 (2021) 103306</a>
Role of the IL-33/amphiregulin pathway as a potential therapeutic target in HIV infection	<a href="#">NCT03622177</a>	Inserm-ANRS	N/A	<a href="#">J Immunol. 2022 May 2;ij2100725.</a>
Seroprevalence of anti-Tat antibodies in South African people with HIV	<a href="#">NCT01359800</a>	CNAIDS, Istituto Superiore di Sanità, Rome, Italy	N/A	N/A
Size of the HIV-1 reservoir and ongoing replication in defined cohorts	UK CPMS16004	University College London/amfAR	N/A	N/A
Specimen repository for HIV immunopathogenesis	<a href="#">NCT03579381</a>	AIDS Healthcare Foundation	N/A	N/A
Tissue drug levels of HIV medications	<a href="#">NCT01490346</a>	University of Minnesota – Clinical and Translational Science Institute/NIAID	N/A	<a href="#">Proc Natl Acad Sci USA. 2014 Feb 11;111(6):2307-12.</a>
<b>ULTRASTOP</b> (Towards HIV Functional Cure) <b>ERAMUNE-03</b> (antiretroviral treatment interruption)	<a href="#">NCT01876862</a>	Objectif Recherche VACcin Sida (ORVACS)/Fondation Bettencourt Schueller	N/A	<a href="#">AIDS, Published Ahead-of-Print, January 4, 2016</a>
<b>VIRECT</b> : Impact of pre-ART CD4 T cell level on the rectal reservoir in long-term HIV-1 treated men	<a href="#">NCT02526940</a>	Centre Hospitalier Universitaire de Saint Etienne	N/A	N/A
<b>PROTEASOME INHIBITORS</b>				
<b>ixazomib</b>	<a href="#">NCT02946047</a>	Mayo Clinic	Phase I	<a href="#">EClinicalMedicine 42:101225.</a>
<b>STEM CELL TRANSPLANTATION</b>				
<b>HIVECT</b> : HIV eradication through cord-blood transplantation	<a href="#">NCT02923076</a>	Puerta de Hierro University Hospital	N/A	N/A
<b>IMPAACT P1107</b> : Cord blood transplantation using CCR5-Δ32 donor cells for the treatment of HIV and underlying disease	<a href="#">NCT02140944</a>	International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)	N/A	<a href="#">Cell. 2023 Mar 16;186(6):1115-1126.e8.</a> <a href="#">CROI 2022, Abstract 65</a> <a href="#">ASH 2018, Abstract 2184</a>
Cord blood transplant with OTS for the treatment of HIV+ hematologic cancers	<a href="#">NCT04083170</a>	Fred Hutchinson Cancer Research Center	Phase II	<a href="#">Study stopped</a> due to end of funding and lack of accrual

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>STEM CELL TRANSPLANTATION (Cont.)</b>				
<b>BMT CTN 0903:</b> Allogeneic transplant in individuals with chemotherapy-sensitive hematologic malignancies and coincident HIV infection	<a href="#">NCT01410344</a>	National Heart, Lung, & Blood Institute/National Cancer Institute/Blood & Marrow Transplant Clinical Trials Network	Phase II	<a href="#">Biol Blood Marrow Transplant. 2019 Jul 4. pii: S1083-8791(19)30417-3. J Clin Oncol. 35, no. 15 suppl (May 2017) 7006-7006.</a>
HLA-mismatched unrelated donor bone marrow transplantation	<a href="#">NCT02793544</a>	Center for International Blood and Marrow Transplant Research	Phase II	<a href="#">HRSA Advisory Council on Blood Stem Cell Transplantation, September 25, 2020</a>
Immune response after stem cell transplant in HIV-positive patients with hematologic cancer	<a href="#">NCT00968630</a>	Fred Hutchinson Cancer Research Center	Phase II	N/A
Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-1 individuals	<a href="#">NCT01836068</a>	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase I	<a href="#">JAIDS 2021 Nov 8. AIDS Res Hum Retroviruses. 2021 Jun 9. Lancet HIV. 2020 Jul 7: S2352-3018(20)30073-4.</a>
<b>STIMULANTS</b>				
<b>EMRLHD:</b> Effect of methamphetamine on residual latent HIV disease study	<a href="#">NCT03825536</a>	University of California, San Francisco	Phase IV	N/A
<b>T-CELL RECEPTOR-BASED BISPECIFICS</b>				
<b>IMC-M113V</b> in HLA-A*02:01 positive people	IMC-M113V-101	Immunocore	Phase I/II	CROI 2023, <a href="#">Abstract 436</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>THERAPEUTIC VACCINES</b>				
<b>AGS-004</b> (personalized therapeutic vaccine utilizing patient-derived dendritic cells and HIV antigens)	<a href="#">NCT00672191</a>	Argos Therapeutics	Phase IIb	<a href="#">JAIDS. 2016 May 1;72(1):31-8</a>
<b>AGS-004</b>	<a href="#">NCT01069809</a>	Argos Therapeutics	Phase IIb	<a href="#">ARHR. 34(1):111-122</a> CROI 2014, <a href="#">Poster abstract 344</a>
<b>iHIVARNA-01</b> (TriMix & HIV antigen naked messenger RNA)	<a href="#">NCT02888756</a>	Rob Gruters, Erasmus Medical Center	Phase IIa	<a href="#">Vaccines (Basel). 2019 Dec 6;7(4). pii: E209.</a>
<b>DermaVir</b> (topically applied DNA vaccine)	<a href="#">NCT00711230</a>	Genetic Immunity	Phase II	N/A
<b>DermaVir</b>	<a href="#">NCT00918840</a>	Genetic Immunity	Phase II	N/A
<b>GSK Biologicals HIV Vaccine 732462</b> (p24-RT-Nef-p17 fusion protein vaccine)	<a href="#">NCT01218113</a>	GlaxoSmithKline	Phase II	<a href="#">Medicine (Baltimore). 2016 Feb;95(6):e2673</a>
<b>GTU-multiHIV + LIPO-5</b> (DNA + lipopeptide vaccines)	<a href="#">NCT01492985</a>	Inserm-ANRS	Phase II	<a href="#">J Virol. 2021 May; 95(9): e02165-20.</a> <a href="#">J Infect Dis. 2019 Jul 2;220:S5-S6</a> <a href="#">AIDS. 2018 Oct 15 HIVR4P 2016, Abstract P27.09</a>
<b>Tat protein vaccine</b>	<a href="#">NCT01513135</a> <a href="#">NCT02712489</a> (extended follow-up study)	CNAIDS, Istituto Superiore di Sanità, Rome, Italy	Phase II	<a href="#">Retrovirology. 2016 Jun 9;13(1):34</a>
<b>Tat protein vaccine</b>	<a href="#">NCT00751595</a> <a href="#">NCT02118168</a> (extended follow-up study)	Barbara Ensoli, MD, Istituto Superiore di Sanità	Phase II	<a href="#">Front. Immunol. February 13, 2019</a> <a href="#">Retrovirology. 2015 Apr 29;12(1):33</a> <a href="#">PLoS One. 2010 Nov 11;5(11):e13540</a>
<b>Vacc-4x</b> (peptide-based vaccine)	<a href="#">NCT01712256</a>	Bionor Immuno AS	Phase II	<a href="#">PLoS One. 2019 Jan 30;14(1):e0210965.</a>
<b>Vacc-4x</b>	<a href="#">NCT00659789</a>	Bionor Immuno AS	Phase II	<a href="#">Lancet Infect Dis. 2014 Apr;14(4):291-300</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)



**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>THERAPEUTIC VACCINES (Cont.)</b>				
VAC-3S (peptide-based vaccine)	<a href="#">NCT02041247</a>	InnaVirVax	Phase II	<a href="#">NPJ Vaccines (2019) 4:1</a> IAS 2017, Abstract MOSY0404 ( <a href="#">slides</a> , <a href="#">video</a> )
VAC-3S	<a href="#">NCT02390466</a>	InnaVirVax	Phase I/IIa	N/A
VAC-3S (peptide-based vaccine)	<a href="#">NCT01549119</a>	InnaVirVax	Phase I/IIa	30 Years of HIV Science, 2013, <a href="#">Poster abstract 145</a>
AGS-004	<a href="#">NCT02042248</a>	University of North Carolina at Chapel Hill/Argos Therapeutics/U.S. National Institutes of Health (NIH)	Phase I/II	N/A
Autologous HIV-1 ApB DC Vaccine	<a href="#">NCT00510497</a>	Sharon Riddler, University of Pittsburgh/NIAID	Phase I/II	<a href="#">J Infect Dis. 2016 May 1;213(9):1400-9</a>
Dendritic cells pulsed with chemically inactivated HIV	<a href="#">NCT02766049</a>	University of Sao Paulo General Hospital	Phase I/II	<a href="#">J. Cellular Immunotherapy xx (2016) 1-10</a> <a href="#">J Int AIDS Soc. 2014 Jan 10;17:18938</a>
Dendritic cell vaccine	<a href="#">NCT00833781</a>	Massachusetts General Hospital	Phase I/II	<a href="#">JAIDS 71(3):246-53.</a>
Dendritic cell vaccine (DCV-2)	<a href="#">NCT00402142</a>	Hospital Clinic of Barcelona	Phase I/II	<a href="#">Sci Transl Med. 2013 Jan 2;5(166):166ra2</a>
DermaVir	<a href="#">NCT00270205</a>	AIDS Clinical Trials Group	Phase I/II	<a href="#">JAIDS. 2013 Dec 1;64(4):351-9</a>
GTU®-MultiHIV B clade vaccine	<a href="#">NCT02457689</a>	Imperial College London	Phase I/II	<a href="#">Front Immunol. 2019 Dec 13;10:2911.</a>
p24CE1/2 + p55 <sup>gag</sup> conserved-element DNA vaccines	<a href="#">NCT03560258</a>	NIAID	Phase I/II	<a href="#">AIDS. 2023 Dec 4.</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>THERAPEUTIC VACCINES (Cont.)</b>				
<b>PENNVAX-GP or INO-6145 + IL-12 DNA adjuvant (INO-9012)</b> (DNA vaccines)	<a href="#">NCT03606213</a>	Steven Deeks, UCSF	Phase I/II	CROI 2023, Abstracts <a href="#">408</a> , <a href="#">428</a> HIV Persistence Workshop 2022, <a href="#">Abstract PP 8.3</a> CROI 2022, <a href="#">Abstract 284</a>
<b>Tat Oyi</b> (protein-based vaccine)	<a href="#">NCT01793818</a>	Biosantech	Phase I/II	<a href="#">Retrovirology. 2016 Apr 1;13:21</a>
<b>THV01</b> (lentiviral vector-based therapeutic vaccine)	<a href="#">NCT02054286</a>	Theravectys S.A.	Phase I/II	N/A
<b>TUTI-16</b> (synthetic HIV-1 Tat epitope vaccine)	<a href="#">NCT01335191</a>	Thymon, LLC	Phase I/II	<a href="#">Hum Vaccin Immunother. 2012 Oct;8(10):1425-30</a>
<b>Vacc-C5</b> (peptide-based vaccine)	<a href="#">NCT01627678</a>	Bionor Immuno AS	Phase I/II	<a href="#">JAIDS April 2018;77:57</a> <a href="#">BMC Infect Dis. 2017 Mar 24;17(1):228</a>
<b>Ad26.Mos4.HIV + MVA-Mosaic or clade C gp140 + mosaic gp140</b> (viral vector vaccines + proteins)	<a href="#">NCT03307915</a>	Janssen Vaccines & Prevention B.V.	Phase I	<a href="#">NPJ Vaccines. 9(1):89.</a>
<b>Ad26.Mos.HIV + MVA-Mosaic</b>	<a href="#">NCT02919306</a>	Janssen Vaccines & Prevention B.V.	Phase I	<a href="#">Cell Rep. 43(6):114344.</a> HIV Persistence Workshop 2022, <a href="#">Abstract PP 8.6</a> <a href="#">Nat Med March 23, 2020.</a>
<b>AFO-18</b> (peptide-based vaccine)	<a href="#">NCT01141205</a>	Statens Serum Institut (SSI)/Ministry of the Interior and Health, Denmark/European and Developing Countries Clinical Trials Partnership (EDCTP)	Phase I	<a href="#">AIDS Res Hum Retroviruses. 2013 Nov;29(11):1504-12</a>
<b>AFO-18</b> (peptide-based vaccine)	<a href="#">NCT01009762</a>	SSI/Rigshospitalet/Hvidovre University Hosp./Ministry of Interior & Health, Denmark	Phase I	<a href="#">Clin Immunol. 2013 Feb;146(2):120-30</a>
<b>AT20-KLH</b>	MED-AT20-001	Medestea Research & Production SpA, Turin	Phase I	<a href="#">Vaccine. 2014 Feb 19;32(9):1072-8</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>THERAPEUTIC VACCINES (Cont.)</b>				
<b>ChAdOx1.HTI, MVA.HTI, ConM SOSIP.v7 gp140</b>	<a href="#">NCT05208125</a>	IrsiCaixa	Phase I	N/A
<b>ChAdV63.HIVconsv + MVA.HIVconsv</b> (viral vector vaccines)	<a href="#">NCT01712425</a>	IrsiCaixa/Fundació Lluita contra la SIDA/Hospital Clinic of Barcelona/ HIVACAT/University of Oxford	Phase I	<a href="#">EClinicalMedicine. 2019 Jun 5;11:65-80.</a> <a href="#">IAS 2015, Poster abstract MOPEA036</a>
<b>Dendritic cells loaded with HIV-1 lipopeptides</b>	<a href="#">NCT00796770</a>	Baylor Research Institute/ANRS	Phase I	<a href="#">PLoS Pathog. 2019 15(9):e1008011.</a> <a href="#">Eur J Immunol. 2014 Sep;44(9):2802-10.</a> <a href="#">Retrovirology 2012, 9(Suppl 2):P328</a>
<b>DermaVir</b>	<a href="#">NCT00712530</a>	Genetic Immunity	Phase I	<a href="#">PLoS One. 2012 7(5): e35416</a>
<b>D-GPE DNA + M-GPE MVA</b> (DNA + viral vector vaccines)	<a href="#">NCT01881581</a>	Centers for Disease Control and Prevention, China	Phase I	N/A
<b>DNA.HTI + MVA.HTI + ChAdOx1.HTI</b> (DNA + viral vector vaccines) (ATI extension)	<a href="#">NCT04385875</a>	Fundacio Lluita Contra la SIDA	Phase I	N/A
<b>DNA.HTI + MVA.HTI + ChAdOx1.HTI</b> (DNA + viral vector vaccines)	<a href="#">NCT03204617</a>	Aelix Therapeutics	Phase I	HIV Persistence Workshop 2022, <a href="#">Abstract OP 8.3 (slides)</a> <a href="#">Nat Med. 2022 Oct 27.</a> CROI 2021, <a href="#">Abstract 161, Webcast</a>
<b>HIVAX</b> (lentiviral vector-based therapeutic vaccine)	<a href="#">NCT01428596</a>	GeneCure Biotechnologies	Phase I	<a href="#">Vaccine. 2020;S0264-410X(20)30485-0</a> <a href="#">Vaccine. 2016;34(19):2225-32</a>
<b>HIV-v</b> (peptide-based vaccine)	<a href="#">NCT01071031</a>	PepTcell Limited	Phase I	<a href="#">Vaccine. 2013 Nov 19;31(48):5680-6</a>
<b>iHIVARNA-01</b> (TriMix & HIV antigen naked messenger RNA)	<a href="#">NCT02413645</a>	Biomedical Research Institute August Pi i Sunyer (IDIBAPS)	Phase I	<a href="#">AIDS. 2018 Nov 13;32(17):2533-2545.</a>
<b>JS7 DNA + MVA62B</b> (DNA + viral vector vaccines)	<a href="#">NCT01378156</a>	GeoVax, Inc.	Phase I	<a href="#">PLoS One. 2016 Oct 6;11(10):e0163164</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>THERAPEUTIC VACCINES (Cont.)</b>				
MAG pDNA vaccine +/- IL-12	<a href="#">NCT01266616</a>	NIAID	Phase I	<a href="#">JAIDS. 2016 Feb 1;71(2):163-71.</a>
MAG-pDNA + rVSV <sub>IN</sub> HIV-1 Gag (DNA + viral vector vaccines)	<a href="#">NCT01859325</a>	NIAID/Profectus Biosciences, Inc.	Phase I	<a href="#">J. Virology May 20, 2020</a> <a href="#">CROI 2019, Poster abstract 392</a> <a href="#">Sci Transl Med. 2017 Dec 6;9(419). pii: eaan8848</a>
MVA.HIVconsv	<a href="#">NCT01024842</a>	University of Oxford/Medical Research Council	Phase I	<a href="#">J Int AIDS Soc. 2017 May 19;20(1):21171.</a>
MVA.tHIVconsv3 +/- MVA.tHIVconsv4 (viral vectors)	<a href="#">NCT03844386</a>	University of North Carolina, Chapel Hill	Phase I	<a href="#">Results posted in clinicaltrials.gov</a>
PENNVAX-B (Gag, Pol, Env) + electroporation	<a href="#">NCT01082692</a>	Inovio Pharmaceuticals	Phase I	<a href="#">Retrovirology 2012, 9(Suppl 2):P276</a>
PENNVAX-B +/- IL-12 or IL-15	<a href="#">NCT00775424</a>	University of Pennsylvania	Phase I	N/A
Recombinant adenovirus type 5 vaccine	<a href="#">NCT02762045</a>	China CDC	Phase I	N/A
rMVA-HIV + rFPV-HIV (viral vector vaccines) in young adults	<a href="#">NCT00107549</a>	NIAID	Phase I	<a href="#">AIDS. 2011 Nov 28; 25(18): 2227-2234</a>
Tat protein vaccine	<a href="#">NCT00505401</a> <a href="#">NCT01024595</a> (extended follow-up study)	CNAIDS, Istituto Superiore di Sanità, Rome, Italy	Phase I	<a href="#">Rev Recent Clin Trials. 2009 Sep;4(3):195-204</a> <a href="#">Vaccine. 2009 May 26;27(25-26):3306-12</a> <a href="#">AIDS. 2008 Oct 18;22(16):2207-9</a>
<b>TOLL-LIKE RECEPTOR AGONISTS</b>				
MGN1703 toll-like receptor 9 (TLR9) agonist	<a href="#">NCT02443935</a>	University of Aarhus	Phase Ib/IIa	<a href="#">EBioMedicine. 2019 Jul 9. pii: S2352-3964(19)30440-2.</a> <a href="#">AIDS. 2019 Mar 29</a> <a href="#">Clin Infect Dis. 2017 Mar 9</a>
Poly-ICLC (TLR3 agonist)	<a href="#">NCT02071095</a>	Nina Bhardwaj, MD/Campbell Foundation/Oncovir, Inc.	Phase I/II	<a href="#">Front Immunol. 2019 Apr 9;10:725.</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>TOLL-LIKE RECEPTOR AGONISTS (Cont.)</b>				
<b>vesatolimod</b> (TLR7 agonist) in ART-treated HIV controllers	<a href="#">NCT03060447</a>	Gilead Sciences	Phase Ib	<a href="#">Front Immunol. 15:1405348.</a> <a href="#">Eur J Immunol. e2350809.</a> Strategies for an HIV Cure 2023, <a href="#">Abstract PP24</a> CROI 2023, <a href="#">Abstract 437</a> <a href="#">EACS 2021</a> , Abstract PE2/1 IAS 2021, <a href="#">Abstract OAA0304 (video)</a> <a href="#">Sci Transl Med. 2021 Jun 23;13(599): eabg3071.</a> CROI 2020, <a href="#">Abstract 40</a> , <a href="#">Webcast</a>
<b>vesatolimod</b> (formerly GS-9620) (TLR7 agonist)	<a href="#">NCT02858401</a>	Gilead Sciences	Phase Ib	<a href="#">Eur J Immunol. e2350809.</a> CROI 2024, <a href="#">Abstract 542</a> <a href="#">CID, ciaa1534</a> IAS 2019, <a href="#">Abstract WEAA0304 (slides)</a>
<b>vesatolimod</b> (TLR7 agonist drug interaction study)	<a href="#">NCT05458102</a>	Gilead Sciences	Phase I	Terminated: Sponsor decision to change the clinical development plan (not based on efficacy or safety concerns)
<b>TRADITIONAL CHINESE MEDICINE</b>				
<b>Triptolide wilfordii</b>	<a href="#">NCT02219672</a>	Peking Union Medical College	Phase III	N/A
<b>TREATMENT INTENSIFICATION/EARLY TREATMENT</b>				
<b>enfuvirtide</b>	<a href="#">NCT00051831</a>	NIAID	Not listed	<a href="#">J Infect Dis. 2010 Jan 15;201(2):293-6</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>				
<b>enfuvirtide</b>	<a href="#">NCT00334022</a>	Canadian Immunodeficiency Research Collaborative	Not listed	N/A
<b>New Era Study:</b> Treatment with multi-drug class (MDC) HAART	<a href="#">NCT00908544</a>	MUC Research GmbH	Not listed	<a href="#">Front Immunol. 2018 Apr 30;9:811</a>
<b>PLUS:</b> Pilot study on the effect of adding raltegravir +/- a second drug on HIV levels in the gut	<a href="#">NCT00884793</a>	University of California, San Francisco	Not listed	<a href="#">J Infect Dis. 2010 Nov 15;202(10):1553-61</a> <a href="#">AIDS. 2010 Oct 23;24(16):2451-60</a>
Anti-HIV medications for people with recent HIV acquisition	<a href="#">NCT00106171</a>	NIAID	Phase IV	<a href="#">PLoS One. 2015 10(11):e0143259</a>
Antiretroviral regime for viral eradication in newborns	<a href="#">NCT02712801</a>	National Center for Women and Children's Health, China CDC	Phase IV	N/A
<b>DIORR:</b> Dolutegravir impact on residual replication	<a href="#">NCT02500446</a>	University of Melbourne	Phase IV	<a href="#">The Lancet HIV, April 8, 2018</a> CROI 2018, <a href="#">Abstract 71</a> , <a href="#">Webcast</a>
<b>DRONE:</b> Impact of starting a dolutegravir-based regimen on HIV-1 proviral DNA reservoir of treatment naïve and experienced patients	<a href="#">NCT02370979</a>	University Hospital, Strasbourg, France	Phase IV	N/A
<b>LEOPARD:</b> Latency and early neonatal provision of antiretroviral drugs clinical trial	<a href="#">NCT02431975</a>	Columbia University	Phase IV	<a href="#">PLoS Pathog. 2022;18(8):e1010751</a> <a href="#">CID, ciab586</a> <a href="#">J Clin Med. 2021 May 12;10(10):2074.</a> <a href="#">EClinicalMedicine 18 (2020) 100241</a>
<b>P25-INACTION:</b> Implication for strategies of long term control of viral replication in patients with primary HIV infection	<a href="#">NCT04225325</a>	Adriano Lazzarin, MD	Phase IV	<a href="#">JAA. 64(2):107200.</a> <a href="#">J Med Virol. 2023 Sep;95(9):e29114.</a> <a href="#">EACS 2021</a> , Abstract BPD4/3

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>				
<b>ANRS 147 OPTIPRIM:</b> Optimization of primary HIV-1 infection treatment	<a href="#">NCT01033760</a>	Inserm-ANRS	Phase III	<a href="#">PLoS One. 2013; 8(5): e64219.</a> <a href="#">PLoS One. 2013; 8(3): e59767</a> IAS 2013, <a href="#">Abstract WEAB0101</a>
<b>maraviroc</b>	<a href="#">NCT00808002</a>	Germans Trias i Pujol Hospital	Phase III	<a href="#">AIDS. 2014 Jan 28;28(3):325–34</a>
<b>raltegravir + maraviroc</b>	<a href="#">NCT00935480</a>	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer	Phase III	N/A
<b>raltegravir</b>	<a href="#">NCT00554398</a>	Germans Trias i Pujol Hospital	Phase III	<a href="#">Antivir Ther. 2012;17(2):355–64</a>
<b>tenofovir/emtricitabine + dolutegravir or tenofovir/emtricitabine + darunavir/cobicistat</b>	<a href="#">NCT02987530</a>	Inserm/ANRS	Phase III	N/A
<b>VIRECURE:</b> Impact of extremely early ART to reduce viral reservoir & induce functional cure of HIV infection	<a href="#">NCT02588820</a>	David Garcia Cinca, Hospital Clinic of Barcelona	Phase III	EACS 2019, <a href="#">Abstract PE38/2</a>
Intense acute infection study	<a href="#">NCT01154673</a>	University of Toronto	Phase II/III	<a href="#">J Virol. 93(6): e01832-18.</a> <a href="#">OFID 2(4): ofv138.</a>
<b>EDIT:</b> Effect of dolutegravir intensification on HIV-1 reservoirs	<a href="#">NCT05351684</a>	University of Liege	Phase II	CROI 2023, <a href="#">Abstract 429</a>
<b>maraviroc</b>	<a href="#">NCT00795444</a>	Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal/Pfizer	Phase II	<a href="#">AIDS. 2013 Aug 24; 27(13):2081-8.</a> <a href="#">PLoS One. 2011; 6(12):e27864</a>
<b>peginterferon alfa-2a (Pegasys)</b>	<a href="#">NCT00594880</a>	Wistar Institute	Phase II	<a href="#">EBioMedicine. 2020 Aug 19;59:102945.</a> <a href="#">J Infect Dis. 2013 Jan 15; 207(2): 213–222</a>
<b>peginterferon alfa-2b</b>	<a href="#">NCT01935089</a>	University of Pennsylvania/Wistar Institute	Phase II	<a href="#">AIDS Res Hum Retroviruses. 2020 Dec 15.</a> CROI 2017, <a href="#">Poster abstract 326</a>

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure September 16, 2024

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>				
<b>peginterferon alfa-2b</b>	<a href="#">NCT02227277</a>	Wistar Institute	Phase II	HIV Persistence Workshop 2019, Abstract PP 4.1 (see <a href="#">abstract book</a> ) CROI 2019, <a href="#">Abstract 136</a> , <a href="#">Webcast</a>
<b>raltegravir</b>	<a href="#">NCT00520897</a>	Canadian Immunodeficiency Research Collaborative	Phase II	<a href="#">AIDS. 2012 Jan 14;26(2):167-74</a>
<b>raltegravir</b>	<a href="#">NCT00807443</a>	Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal	Phase II	<a href="#">AIDS. 2012 Sep 24;26(15):1885-94</a>
Viral suppression after analytic treatment interruption in Thai patients who initiated HAART during acute HIV infection	<a href="#">NCT02614950</a>	South East Asia Research Collaboration with Hawaii	Phase II	<a href="#">Nat Med. 2018 Jul;24(7):923-926.</a> CROI 2017, <a href="#">Abstract 124</a> , <a href="#">Webcast</a>
<b>alpha interferon intensification</b>	<a href="#">NCT01295515</a>	NIAID	Phase I/II	N/A
<b>indinavir + zidovudine + lamivudine + nevirapine</b>	<a href="#">NCT00001644</a>	NIAID	Phase I	N/A

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)